U.S. patent number RE38,442 [Application Number 09/798,641] was granted by the patent office on 2004-02-24 for nucleic acid amplification method hybridization signal amplification method (hsam).
This patent grant is currently assigned to Mount Sinai School of Medicine. Invention is credited to Margaret Brandwein, David Y. Zhang.
United States Patent |
RE38,442 |
Zhang , et al. |
February 24, 2004 |
Nucleic acid amplification method hybridization signal
amplification method (HSAM)
Abstract
An improved method allowing for rapid sensitive and standardized
detection of a target nucleic acid from a pathogenic microorganism
or virus or normal or abnormal gene in a sample is provided. The
method involves hybridizing a target nucleic acid to several
non-overlapping oligonucleotide probes that hybridize to adjacent
regions in the target nucleic acid, the probes being referred to
capture/amplification probes and amplifications probes,
respectively, in the presence of paramagnetic beads coated with a
ligand binding moiety. Through the binding of a ligand attached to
one end of the capture/amplification probe and the specific
hybridization of portions of the probes to adjacent sequences in
the target nucleic acid, a complex comprising the target nucleic
acid, the probes and the paramagnetic beads is formed. The probes
may then ligated together to form a contiguous ligated
amplification sequence bound to the beads, which complex may be
denatured to remove the target nucleic acid and unligated probes.
Alternatively, separate capture and amplification probes may be
used which form continuous full-length or circular probes, and may
be directly detected or amplified using a suitable amplification
technique, e.g., PCR, RAM or HSAM for detection. The detection of
the ligated amplification sequence, either directly or following
amplification of the ligated amplification sequence, indicates the
presence of the target nucleic acid in a sample. Methods for the
detection of the ligated amplification sequence, including
hybridization signal amplification method and ramification-
extension amplification method, are also provided.
Inventors: |
Zhang; David Y. (Jamaica,
NY), Brandwein; Margaret (Jamaica, NY) |
Assignee: |
Mount Sinai School of Medicine
(New York, NY)
|
Family
ID: |
31499256 |
Appl.
No.: |
09/798,641 |
Filed: |
March 2, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
PCTUS9507671 |
Jun 14, 1995 |
|
|
|
|
596331 |
May 20, 1996 |
|
|
|
|
263937 |
Jun 22, 1994 |
|
|
|
Reissue of: |
690495 |
Jul 31, 1996 |
05876924 |
Mar 2, 1999 |
|
|
Current U.S.
Class: |
435/5; 435/6.11;
435/7.1; 435/7.9; 435/91.2; 536/23.1; 536/24.3; 536/24.32;
536/24.33 |
Current CPC
Class: |
C12Q
1/6813 (20130101); C12Q 1/682 (20130101); C12Q
1/6834 (20130101); C12Q 1/6844 (20130101); C12Q
1/6853 (20130101); C12Q 1/686 (20130101); C12Q
1/6862 (20130101); C12Q 1/6865 (20130101); C12Q
1/6813 (20130101); C12Q 1/682 (20130101); C12Q
1/6834 (20130101); C12Q 1/6853 (20130101); C12Q
1/686 (20130101); C12Q 1/6862 (20130101); C12Q
1/6865 (20130101); G01N 33/536 (20130101); C12Q
2563/131 (20130101); C12Q 2563/143 (20130101); C12Q
2565/519 (20130101); C12Q 2563/131 (20130101); C12Q
2563/143 (20130101); C12Q 2565/519 (20130101); C12Q
2563/131 (20130101); C12Q 2563/143 (20130101); C12Q
2565/519 (20130101); C12Q 2563/131 (20130101); C12Q
2563/143 (20130101); C12Q 2565/519 (20130101); C12Q
2563/131 (20130101); C12Q 2563/143 (20130101); C12Q
2565/519 (20130101); C12Q 2563/131 (20130101); C12Q
2563/143 (20130101); C12Q 2565/519 (20130101); C12Q
2563/131 (20130101); C12Q 2563/143 (20130101); C12Q
2565/519 (20130101) |
Current International
Class: |
C12Q
1/68 (20060101); C12Q 001/70 (); C12Q 001/68 ();
G01N 033/53 (); G12P 019/36 (); C07H 021/04 () |
Field of
Search: |
;435/6,5,7.1,7.9,91.2
;536/23.1,24.3,24.32,24.33 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
0324616 |
|
Jul 1989 |
|
EP |
|
0357336 |
|
Mar 1990 |
|
EP |
|
0481704 |
|
Apr 1992 |
|
EP |
|
0657548 |
|
Jun 1995 |
|
EP |
|
0185494 |
|
Jun 1996 |
|
EP |
|
262799 |
|
Sep 1992 |
|
JP |
|
304900 |
|
Oct 1992 |
|
JP |
|
9001065 |
|
Feb 1990 |
|
WO |
|
9212261 |
|
Jul 1992 |
|
WO |
|
9313223 |
|
Jul 1993 |
|
WO |
|
9513396 |
|
May 1995 |
|
WO |
|
Other References
Akane et al. (1994) Biotechniques 16:238.* .
Barany (1991) Proc. Natl. Acad. Sci. US 88:189.* .
Boddinghaus et al. (1990) J. Clin. Micro. 28:1751.* .
Biebricher et al. (1986) Nature 321:89.* .
Bukh et al. (1992) Proc. Natl. Acad. Sci. 89:187.* .
Chetverin et al. (1991) J. Mol. Biol. 222:3.* .
Gretch et al. (1994) J. Infect. Dis. 169:1219.* .
Guatelli et al. (1990) Proc. Natl. Acad. USA 87:1874.* .
Keller et al. (1993) DNA Probes, Stockton Press pp. 28-30.* .
Lee et al. (1992) J. Clin. Micro. 30:1602.* .
Lomell et al. (1989 Clin. Chem. 35:1826.* .
Nickerson et al. (1990) Proc. Natl. Acad. Sci. 87:8923.* .
Numata et al. (1993) J. Med. Virol. 41:120.* .
Nuovo (1994) PCR In Situ Hybribizaition: Protocols and Applications
(2 ed.) Raven Press. NY pp. 36-43, 54-58.* .
Patterson et al. (1993) Science 260:976.* .
Rogall et al. (1990) J. Gen. Micro. 136:1915.* .
Sakai et al. (1988) Science 239:487.* .
Sakai et al. (1985) Science 230: 1350.* .
Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2nd
edition) Cold Spring Laboratory.* .
Schaffner et al. (1977) J. Mol. Biol. 117:877.* .
Sokolova et al. (1988) FEBS Letters 232:153.* .
Walker et al. (1992) Nucleic Acids Res. 20:1691.* .
Wu et al. (1992) Proc. Natl. Acad. Sci. USA 89:11769.* .
Zhang (1992) Ph.D. Thesis. New York University. Section 4.2.5, pp.
84-85, 100-101.* .
Promega, Technical Manual, PolyATract mRNA Isolation Systems.*
.
Sherman et al. (1993) J. Clin. Microbiol. 31:2679.* .
Urdea (1991) Nucleic Acids Reseasrch Symposium Series No. 24:197.*
.
Urdea (1994) Bio/Technology 12:926.* .
Walker et al. (1992) Proc. Natl. Acad. Sci. 89:392.* .
Zecchini et al. (1995) BioTechniques 19:286.* .
Niemeyer et al. (1994) Nucleic Acids Research 22:5530..
|
Primary Examiner: Siew; Jeffrey
Assistant Examiner: Tung; Joyce
Attorney, Agent or Firm: Stroock & Stroock & Lavan
LLP
Parent Case Text
BACKGROUND OF THE INVENTION
The present application is a continuation-in-part of pending
International Application PCT/US95/07671 filed Jun. 14, 1995, and
continuation-in-part of corresponding to pending U.S. application
Ser. No. 08/596,331, filed May 20, 1996 which application is a
continuation-in-part of U.S. application Ser. No. 08/263,937 filed
June 22, 1994 now abandoned.
Claims
We claim:
1. A method for detecting a target nucleic acid in a sample
comprising: (a) contacting said nucleic acid in said sample in a
reaction vessel under conditions that allow nucleic acid
hybridization between complementary sequences in nucleic acids with
oligonucleotide probes .[.in the presence of a paramagnetic
particles coated with a ligand binding moiety, said oligonucleotide
probes comprising one or more capture probes, each having a 3'
nucleotide sequence that is neither complementary nor hybridizable
to a nucleotide sequence in the target nucleic acid, and a 5'
nucleotide sequence that is complementary and hybridizable to a
nucleotide sequence in the target nucleic acid, or a 5' nucleotide
sequence that is neither complementary nor hybridizable to a
nucleotide sequence in the target nucleic acid, and a 3' nucleotide
sequence that is complementary and hybridizable to a nucleotide
sequence in the target nucleic acid, each capture probe further
having a ligand bound to the non-complementary sequence of the
probe, wherein said ligand that binds to and an forms affinity pair
with said ligand binding moiety coated onto said paramagnetic
particles;.]. .Iadd., wherein .Iaddend.said oligonucleotide probes
further .[.comprising.]. .Iadd.comprise .Iaddend.a circularizable
probe having 3' and 5' regions that are complementary to adjacent
but noncontiguous sequences in the target nucleic acid, said 3' and
5' regions separated by a linker region that is neither
complementary nor hybridizable to a nucleotide sequence in the
target nucleic acid and wherein said linker region comprises at
least one pair of adjacent nucleotide sequences each pair of which
is complementary and hybridizable to the 5' and 3' nucleotide
sequences of a signal probe, such that a complex is formed
comprising the target nucleic acid.[.,.]. .Iadd.and the
.Iaddend.circularizable probe, .[.capture probes and said
paramagnetic particles, wherein the capture probes are hybridized
to the complementary nucleotide sequences in the target nucleic
acid and are bound to the paramagnetic particles through the
binding of the ligand on the capture probe to the ligand binding
moiety on the paramagnetic particles, and.]. .Iadd.wherein
.Iaddend.the circularizable probe is bound on its 3' and 5' ends to
adjacent but noncontiguous sequences in the target nucleic acid;
(b) .[.separating the complex from unbound reactants and.]. washing
the complex; (c) adding a ligating agent that joins the 3' end and
5' end of said circularizable probe and adding a multiplicity of
circularizable nucleic acid signal probes having 3' and 5'
nucleotide sequences that are complementary and hybridizable to
adjacent regions of the linker region of the circular probe bound
to the target, or of other signal probes, and having linker regions
comprising at least one pair of adjacent nucleotide sequences that
are complementary and hybridizable to the 5' and 3' nucleotide
sequences of one of the multiplicity of signal probe, such that a
cluster of circular molecules is formed on the target nucleic acid;
(d) washing the target bound cluster to remove probes not bound to
the target nucleic acid; and (e) detecting said target bound
cluster, wherein the detection thereof indicates the presence of
the target nucleic acid in the sample.
2. A method for in situ detection of a target nucleic acid in a
sample comprising the steps of: (a) preparing a tissue sample from
a histological specimen to be analyzed for the presence of the
target nucleic acid; (b) washing said tissue sample; (c) adding a
circularizable nucleic acid probe having 3' and 5' regions that are
complementary to adjacent but noncontiguous sequences in the target
nucleic acid, said 3' and 5' regions separated by a linker region
that is neither complementary nor hybridizable to a nucleotide
sequence in the target nucleic acid wherein said linker region is
labeled with a ligand, such that a complex is formed comprising the
target nucleic acid and circularizable probe; (d) ligating the 3'
and 5' ends of said circularizable probe with a ligating agent that
joins nucleotide sequences such that a circular probe is formed;
(e) washing the complex; (f) adding a ligand binding moiety that
binds to and forms an affinity pair with said ligand and an
oligonucleotide signal probe internally labeled with said ligand
whereby said ligand binding moiety binds to said ligand on said
circular probe and also to said ligand on said oligonucleotide
signal probe to form a labeled complex; (g) washing said labeled
complex to remove unbound signal probe and ligand binding moieties;
and (h) detecting said labeled complex, wherein the detection
thereof indicates the presence of the target nucleic acid in the
sample.
3. A method for in situ detection of a target nucleic acid in a
sample comprising the steps of: (a) preparing a tissue sample from
a histological specimen to be analyzed for the presence of the
target nucleic acid; (b) washing said tissue sample; (c) adding a
circularizable nucleic acid probe having 3' and 5' regions that are
complementary to adjacent but noncontiguous sequences in the target
nucleic acid, said 3' and 5' regions separated by a linker region
that is neither complementary nor hybridizable to a nucleotide
sequence in the target nucleic acid and wherein said linker region
comprises at least one pair of adjacent nucleotide sequences each
pair of which is complementary and hybridizable to the 5' and 3'
nucleotide sequences of a signal probe, such that a complex is
formed comprising the target nucleic acid and circularizable probe,
wherein the circularizable probe is bound on its 3' and 5' ends to
adjacent but noncontiguous sequences in the target nucleic acid;
(d) adding a ligating agent that joins nucleotides sequences and
adding a multiplicity of signal probes having 3' and 5' nucleotide
sequences that are complementary and hybridizable to adjacent
regions of the linker region of the circular probe bound to the
target, or of other signal probes, and having linker regions
comprising at least one pair of adjacent nucleotide sequences that
are complementary and hybridizable to the 5' and 3' nucleotide
sequences of one of the multiplicity of signal probes, such that a
cluster of circular molecules is formed on the target nucleic acid;
(e) washing the target bound cluster to remove probes not bound to
the target nucleic acid; and (f) detecting said target bound
cluster, wherein the detection thereof indicates the presence of
the target nucleic acid in the sample.
4. The method of claim 2 wherein said ligand is selected from the
group consisting of biotin, antigens, haptens, antibodies, heavy
metal derivatives, and polynucleotides including poly dG, polydT,
polydC, polydA and polyU.
5. The method of claim 2 wherein said ligand binding moiety is
selected from the group consisting of streptavidin, avid,
antibodies, antigens, thio groups and polynucleotides including
poly dC, poly dA, poly dG, poly dT and poly U.
6. The method of claim 2 wherein said ligand is biotin and said
ligand binding moiety is streptavidin.
7. The method of claim 2 wherein said ligating agent is a DNA or
RNA ligase.
8. The method of claim 3 wherein said ligating agent is a DNA or
RNA ligase.
9. The method of claim .[.1.]. .Iadd.16 or 17, .Iaddend.wherein
said ligand is selected from the group consisting of biotin,
antigens, haptens, antibodies, heavy metal derivatives, and
polynucleotides including poly dG, polydT, polydC, polydA and
polyU.
10. The method of claim .[.1.]. .Iadd.16 or 17, .Iaddend.wherein
said ligand binding moiety is selected from the group consisting of
streptavidin, avidin, antibodies, antigens, thio groups and
polynucleotides including poly dC, poly dA, poly dG, poly dT and
poly U.
11. The method of claim .[.1.]. .Iadd.16 or 17, .Iaddend.wherein
said ligand is biotin and said ligand binding moiety is
streptavidin.
12. The method of claim 1 .Iadd.or 17, .Iaddend.wherein said
ligating agent is a DNA or RNA ligase.
13. The method of claim .[.1.]. .Iadd.16 .Iaddend.further
comprising subjecting .[.the.]. .Iadd.said .Iaddend.paramagnetic
particles to a magnetic field sufficient to prevent loss of the
particles from the reaction vessel during the separating and
washing steps.
14. A method for detecting an antigen in a sample comprising: (a)
contacting said antigen in said sample with an antibody to said
antigen wherein said antibody is labeled with a ligand under
conditions whereby an antigen/antibody complex is formed; (b)
washing said complex to remove unbound antibody; (c) adding
ligand-binding molecules that are at least divalent for said ligand
and a ligand-labeled nucleic acid probe labeled with at least two
molecules of ligand under conditions whereby ligand-binding
molecules bind to said ligand-labeled antibody and said
ligand-labeled nucleic acid probe such that a complex of antigen,
ligand-labeled antibody, ligand-binding molecules, and
ligand-labeled nucleic acid probes is formed; and (d) detecting
said complex in the absence of nucleic acid amplification, wherein
detection thereof is indicative of the presence of said antigen in
said sample.
15. A method for detecting an antibody in a sample comprising: (a)
contacting said antibody in said sample with an antigen to said
antibody wherein said antigen is labeled with a ligand under
conditions whereby an antigen/antibody complex is formed; (b)
washing said complex to remove unbound antigen; (c) adding
ligand-binding molecules that are at least divalent for said ligand
and a ligand-labeled nucleic acid probe labeled with at least two
molecules of ligand under conditions whereby ligand-binding
molecules bind to said ligand-labeled antigen and said
ligand-labeled nucleic acid probe such that a complex of antibody,
ligand-labeled antigen, ligand-binding molecules, and
ligand-labeled nucleic acid probes is formed; and (d) detecting
said complex in the absence of nucleic acid amplification, wherein
detection thereof is indicative of the presence of said antibody in
said sample. .Iadd.
16. The method of claim 1, wherein (i) the contacting recited in
step (a) occurs in the presence of paramagnetic particles coated
with a ligand binding moiety, wherein the oligonucleotide probes
comprise one or more capture probes each having a 3' nucleotide
sequence that is neither complementary nor hybridizable to a
nucleotide sequence in the target nucleic acid, and a 5' nucleotide
sequence that is complementary and hybridizable to a nucleotide
sequence in the target nucleic acid, or a 5' nucleotide sequence
that is neither complementary nor hybridizable to a nucleotide
sequence in the target nucleic acid, and 3' nucleotide sequence
that is complementary and hybridizable to a nucleotide sequence in
the target nucleic acid, each capture probe further having a ligand
bound to the non-complementary sequence of the probe, wherein said
ligand binds to and forms an affinity pair with the ligand binding
moiety; and (ii) wherein the complex formed in step (a) further
includes the capture probes and the paramagnetic
particles..Iaddend..Iadd.
17. A method for detecting a target nucleic acid in a sample
comprising: (a) contacting the nucleic acid in the sample under
conditions that allow nucleic acid hybridization between
complementary sequences in nucleic acids with oligonucleotide
probes, wherein said oligonucleotide probes comprise circularizable
probes having 3' and 5' regions that are complementary to adjacent
but noncontiguous sequences in the target nucleic acid, said 3' and
5' regions separated by a linker region that is neither
complementary nor hybridizable to a nucleotide sequence in the
target nucleic acid and wherein said linker region is labeled with
a ligand, such that a complex is formed comprising the target
nucleic acid and the circularizable probe; (b) ligating the 3' and
5' end of the circularizable probe with a ligating agent such that
circular probe is formed; (c) washing the complex; (d) adding a
ligand binding moiety that binds to and forms an affinity pair with
the ligand and an oligonucleotide signal probe internally labeled
with the ligand whereby the ligand binding moiety binds to the
ligand on the circular probe and also to the ligand on the
oligonucleotide signal probe to form a labeled complex; (e) washing
the labeled complex to remove the unbound signal probe and the
ligand binding moieties; and (f) detecting the labeled complex,
wherein the detection thereof indicates the presence of the target
nucleic acid in the sample..Iaddend.
Description
TECHNICAL FIELD
The present invention relates to assays and kits for carrying out
said assays for the rapid, automated detection of infectious
pathogenic agents and normal and abnormal genes.
BACKGROUND OF THE INVENTION
A number of techniques have been developed recently to meet the
demands for rapid and accurate detection of infectious agents, such
as viruses, bacteria and fungi, and detection of normal and
abnormal genes. Such techniques, which generally involve the
amplification and detection (and subsequent measurement) of minute
amounts of target nucleic acids (either DNA or RNA) in a test
sample, include inter alia the polymerase chain reaction (PCR)
(Saiki, et al., Science 230:1350, 1985; Saiki et al., Science
239:487, 1988; PCR Technology, Henry A. Erlich, ed., Stockton
Press, 1989; Patterson et al., Science 269:976, 1993), ligase chain
reaction (LCR) (Barany, Proc. Natl. Acad. Sci. USA 88:189, 1991),
strand displacement amplification (SDA) (Walker et al., Nucl. Acids
Res. 20:1691, 1992), Q.beta. replicase amplification (Q.beta.RA)
(Wu et al., Proc. Natl. Acad. Sci. USA 89:11769, 1992; Lomeli et
al., Clin. Chem. 35:1826, 1989) and self-sustained replication
(3SR) (Guatelli et al., Proc. Natl. Acad. Sci. USA 87:1874-1878,
1990). While all of these techniques are powerful tools for the
detection and identification of minute amounts of a target nucleic
acid in a sample, they all suffer from various problems which have
prevented their general applicability in the clinical laboratory
setting for use in routine diagnostic techniques.
One of the most difficult problems is preparation of the target
nucleic acid prior to carrying out its amplification and detection.
This process is time and labor intensive and, thus, generally
unsuitable for a clinical setting, where rapid and accurate results
are required. Another problem especially for PCR and SDA, is that
conditions for amplifying the target nucleic acid for subsequent
detection and optional quantitation vary with each test, i.e.,
there are no constant conditions favoring test standardization.
This latter problem is especially critical for the quantitation of
a target nucleic acid by competitive PCR and for the simultaneous
detection of multiple target nucleic acids.
Circumvention of the aforementioned problems would allow for
development of rapid standardized assays, utilizing the various
techniques mentioned above, that would be particularly useful in
performing epidemiologic investigations, as well as in the clinical
laboratory setting for detecting pathogenic microorganisms and
viruses in a patient sample. Such microorganisms cause infectious
diseases that represent a major threat to human health. The
development of standardized and automated analytical techniques and
kits therefor, based on rapid nd sensitive identification of target
nucleic acids specific for an infectious disease agent would
provide advantages over techniques involving immunologic or culture
detection of bacteria and viruses.
Reagents may be designed to be specific for a particular organism
or for a range of related organisms. These reagents could be
utilized to directly assay microbial genes conferring resistance to
various antibiotics and virulence factors resulting in disease.
Development of rapid standardized analytical techniques will aid in
the selection of the proper treatment.
In some cases, assays having a moderate degree of sensitivity (but
high specificity) may suffice, e.g., in initial screening tests. In
other cases, great sensitivity (as well as specificity) is
required, e.g., the detection of the HIV genome in infected blood
may require finding the virus nucleic acid sequences present in a
sample of one part per 10 to 100,000 human genome equivalents
(Harper et al., Proc. Nat'l, Acad. Sci., USA (83:772, 1986).
Blood contaminants, including inter alia, HIV, HTLV-I, hepatitis B
and hepatitis C, represent a serious threat to transfusion patients
and the development of routine diagnostic tests involving the
nucleic acids of these agents for the rapid and sensitive detection
of such agents would be of great benefit in the clinical diagnostic
agree laboratory. For example, the HIV genome can be detected in a
blood sample using PCR techniques, either as an RNA molecule
representing the free viral particle or as a DNA molecule
representing the integrated provirus (Ou et al., Science 239:295,
1988; Murakawa et al., DNA 7:287, 1988).
In addition, epidemiologic investigations using classical culturing
techniques have indicated that disseminated Mycobacterium
avium-intracellulaire (MAI) infection is a complication of
late-stage Acquired Immunodeficiency Syndrome (AIDS) in children
and adults. The precise extent of the problem is not clear,
however, since current cultural methods for detecting mycobacteria
are cumbersome, slow and of questionable sensitivity. Thus, it
would be desirable and highly beneficial to device a rapid,
sensitive and specific technique for MAI detection in order to
provide a definitive picture of the involvement in HIV-infected and
other immunosuppressed individuals. Such studies must involve
molecular biological methodologies, based on detection of a target
nucleic acid, which have routinely been shown to be more sensitive
than standard culture systems (Boddinghaus et al., J. Clin. Med.
28:1751, 1990).
Other applications for such techniques include detection and
characterization if single gene genetic disorders in individuals
and in populations (see, e.g., Landergren et al., Science 241:
1077, 1988 which discloses a ligation technique for detecting
single gene defects, including point mutations). Such techniques
should be capable of clearly distinguishing single nucleotide
differences (point mutations) that can result in disease (e.g.,
sickle cell anemia) as well as deleted or duplicated genetic
sequences (e.g., thalassemia).
The methods referred to above are relatively complex procedures
that, as noted, suffer from drawbacks making them difficult to use
in the clinical diagnostic laboratory for routine diagnosis and
epidemiological studies of infectious diseases and genetic
abnormalities. All of the methods described involve amplification
of the target nucleic acid to be detected. The extensive time and
labor required for target nucleic acid preparation, as well as
variability in amplification templates (e.g., the specific target
nucleic acid whose detection is being measured) and conditions,
render such procedures unsuitable for standardization and
automation required in a clinical laboratory setting.
The present invention is direction to the development of rapid,
sensitive assays useful for the detection and monitoring of
pathogenic organisms, as well as the detection of abnormal genes in
an individual. Moreover, the methodology of the present invention
can be readily standardized and automated for use in the clinical
laboratory setting.
SUMMARY OF THE INVENTION
An improved method, which allows for rapid, sensitive and
standardized detection and quantitation of nucleic acids from
pathogenic microorganisms from samples from patients with
infectious diseases has now been developed. The improved
methodology also allows for rapid and sensitive detection and
quantitation of genetic variations in nucleic acids in samples from
patients with genetic diseases or neoplasia.
This method provides several advantages over prior art methods. The
method simplifies the target nucleic acid isolation procedure,
which can be performed in microtubes, microchips or micro-well
plates, if desired. The method allows for isolation, amplification
and detection of nucleic acid sequences corresponding to the target
nucleic acid of interest to be carried out in the same sample
receptacle, e.g., tube or micro-well plate. The method also allows
for standardization of conditions, because only a pair of generic
amplification probes may be utilized in the present method for
detecting a variety of target nucleic acids, thus allowing
efficient multiplex amplification. The method also allows the
direct detections of RNA by probe amplification without the need
for DNA template production. The amplification probes, which in the
method may be covalently joined end to end, form a contiguous
ligated amplification sequence. The assembly of the amplifiable DNA
by ligation increases specificity, and makes possible the detection
of a single mutation in a target. This ligated amplification
sequence, rather than the target nucleic acid, is either directly
detected or amplified, allowing for substantially the same
amplification conditions to be used for a variety of different
infectious agents and, thus, leading to more controlled and
consistent results being obtained. In addition, multiple infectious
agents in a single sample may be detected using the multiplex
amplification methodology disclosed.
Additional advantages of the present invention include the ability
to automate the protocol of the method disclosed, which is
important in performing routine assays, especially in the clinical
laboratory and the ability of the method to utilize various nucleic
acid amplification systems, e.g., polymerase chain reaction (PCR),
strand displacement amplification (SDA), ligase chain reaction
(LCR) and self-sustained sequence replication (3SR).
The present method incorporated magnetic separation techniques
using paramagnetic particles or beads coated with a ligand binding
moiety that recognizes and binds to a ligand on an oligonucleotide
capture probe to isolate a target nucleic acid (DNA or RNA) from a
sample of a clinical specimen containing e.g., a suspected
pathogenic microorganism or gene abnormality, in order to
facilitate detection of the underlying disease-causing agent.
.Iadd.Techniques for the detection of target nucleic acids using
hybridizable oligonucleotide probes include the usage of a variety
of solid supports as a physical foundation or substrate for
oligonucleotide probes when they comprise a ligand-binding moiety.
These solid supports, as is well knwon in the art, provide
mechanical support and a solid surface for the binding
oligonucleotide sequences and include paramagnetic beads,
non-paramagnetic beads, a coated test well or vessel, a dipstick, a
microtitre well, a separation column that may include beads, or a
sepharose column. For example, suitable detection methods may be
found inter alia, in Sambrook et al., Molecular Cloning--A
Laboratory Manual, 2.sup.nd edit., Cold Spring Harbor, 1989, in
Methods of Enzymology, Volume 152, Academic Press (1987), or Wu et
al., Recombinant DNA Methodology, Academic Press
(1989)..Iaddend.
In one aspect of the present invention, a target nucleic acid is
hybridized to a pair of non-overlapping oligonucleotide
amplification probes in the presence of paramagnetic beads coated
with a ligand binding moiety, e.g., streptavidin, to form a
complex. These probes are referred to as a capture/amplification
probe and an amplification probe, respectively. The
capture/amplification probe contains a ligand, e.g., biotin, that
is recognized by and binds to the ligand binding moiety on the
paramagnetic beads. The probes are designed so that each contains
generic sequences (i.e., not target nucleic acid specific) and
specific sequences complementary to a nucleotide sequence in the
target nucleic acid. The specific sequences of the probes are
complementary to adjacent regions of the target nucleic acid, and
thus do not overlap one another. Subsequently, the two probes are
joined together using a ligating agent to form a contiguous ligated
amplification sequence. The ligating agent may be an enzyme, e.g.,
DNA ligase or a chemical. Following washing and removal of unbound
reactants and other materials in the sample, the detection of the
target nucleic acid in the original sample is determined by
detection of the ligated amplification sequence. The ligated
amplification sequence may be directly detected if a sufficient
amount (e.g., 10.sup.6 -10.sup.7 molecules) of target nucleic acid
was present in the original sample. If an insufficient amount of
target nucleic acid (<10.sup.6 molecule) was present in the
sample, the ligated amplification sequence (not the target nucleic
acid) may be amplified using suitable amplification techniques,
e.g. PCR, for detection. Alternatively, capture and amplification
functions may be performed by separate and independent probes. For
example, two amplification probes may be ligated to form a
contiguous sequence to be amplified. Unligated probes, as well as
the target nucleic acid, are not amplified in this technique. Yet
another alternative is a single amplification probe that hybridizes
to the target such that its 3' and 5' ends are juxtaposed. The ends
are then ligated by DNA ligase to form a covalently linked circular
probe that can be identified by amplification.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a generic schematic diagram showing the various
components used in the present method of capture,
ligation-dependent amplification and detection of a target nucleic
acid.
FIG. 2 is a schematic flow diagram generally showing the various
steps in the present method.
FIG. 3 is an autoradiograph depicting the detection of a PCR
amplified probe that detects HIV-1 RNA. Lane A is the ligated
amplification sequence according to the invention; lane B, which is
a control, is PCR amplified nanovariant DNA, that does not contain
any HIV-1-specific sequences.
FIG. 4 is a schematic diagram of an embodiment of the present
invention showing the various components used for capture and
ligation-dependent detection of a target nucleic acid, e.g. HCV
RNA, and subsequent amplification of its sequences, employing two
capture/amplification probes containing a bound biotin moiety and
two ligation-dependent amplification probes.
FIG. 5 is a schematic flow diagram showing magnetic isolation,
target specific ligation and PCR amplification for the detection of
HCV RNA using a single capture/amplification probe and two
amplification probes.
FIG. 6 is a schematic diagram showing the various components used
to amplify and detect a target nucleic acid e.g. HCV RNA, employing
two capture/amplification probes, each containing a bound biotin
moiety, and a single amplification probe.
FIG. 7 is a schematic diagram showing various components used to
detect a target nucleic acid e.g. HCV RNA, employing two
capture/amplification probes, each containing a bound biotin
moiety, and a single amplifications probe that circularizes upon
hybridization to the target nucleic acid and ligation of free
termini.
FIG. 8 is a photograph of ethidium bromide stained DNA depicting
PCR amplified probes used to detect HCV RNA in a sample. The amount
of HCV RNA in the sample is determined by comparing sample band
densities to those of standard serial dilution of HCV
transcripts.
FIG. 9 is a photograph of ethidium bromide stained DNA depicting
PCR amplified single, full length ligation-dependent and
circularizable probes used to detect HCV RNA in a sample. The
amount of HCV RNA in the sample is determined by comparing sample
band densities to those of standard serial dilutions of HCV
transcripts.
FIG. 10 is a schematic diagram illustrating the capture and
detection of a target nucleic acid by the hybridization signal
amplification method (HSAM).
FIG. 11 is a schematic diagram illustrating the use of HSAM to
detect an antigen with a biotinylated antibody and biotinylated
signal probes.
FIGS. 12A and 12B are schematic diagrams illustrating RNA-protein
crosslinks formed during formalin fixation. FIG. 12A depicts the
prevention of primer extension due to the crosslinks in the method
of reverse transcription PCR (RT-PCR). FIG. 13B illustrates that
hybridization and ligation of the probes of the present invention
are not prevented by protein-RNA crosslinks.
FIG. 13 is a schematic diagram of multiplex PC. Two set of
capture/amplification probes, having specificity for HIV-1 and HCV,
respectively, are used for target capture, but only one pair of
generic PCR primers is used to amplify the ligated probes. The
presence of each target can be determined by the size of the
amplified product or by enzyme-linked immunosorbent assay.
FIG. 14 is a schematic diagram of HSAM using a circular target
probe and three circular signal probes. AB, CD and EF indicate
nucleotide sequences in the linker regions that are complementary
to the 3' and 5' nucleotide sequences of a circular signal probe.
AB', CD' and EF' indicate the 3' and 5' nucleotide sequences of the
signal probes that have been juxtaposed by binding to the
complementary sequences of the linker regions of another circular
signal probe.
FIG. 15 is a schematic diagram of HSAM utilizing a circular target
probe and linear signal probes.
FIG. 16 is a schematic diagram of amplification of a circularized
probe by primer-extension/displacement and PCR.
FIG. 17 is a schematic diagram of an embodiment of RAM in which a
T3 promoter has been incorporated into Ext-primer 2, allowing
amplification of the circular probe by transcription.
FIG. 18 provides a polyacrylamide gel depicting the amplification
of a circular probe by extension of Ext-primer 1.
FIG. 19 is a schematic diagram of amplification of a circularized
probe by the ramification-extension amplification method (RAM).
FIG. 20 is a diagram of a RAM assay in which an RNA polymerase
promoter sequence is incorporated into the primer.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed towards simplified sample
preparation and generic amplification systems for use in clinical
assays to detect and monitor pathogenic microorganisms in a test
sample, as well as to detect abnormal genes in an individual.
Generic amplification systems are described for clinical use that
combine magnetic separation techniques with ligation/amplification
techniques for detecting and measuring nucleic acids in a sample.
The separation techniques may be combined with most amplification
systems, including inter alia, PCR, LCR and SDA amplification
techniques. The present invention further provides alternative
amplification systems referred to as ramification-extension
amplification method (RAM) and hybridization signal amplifications
(HSAM) that are useful in the method of the present invention. The
advantages of the present invention include (1) suitability for
clinical laboratory settings, (2) ability to obtain controlled and
consistent (standardizable) results, (3) ability to quantitate
nucleic acids in a particular sample, (4) ability to simultaneously
detect and quantitate multiple target nucleic acids in a test
sample, (5) ability to sensitively and efficiently detect nucleic
acids in serum samples and in situ, and (6) ability to detect a
single mutation in a target. Moreover, the complete protocol of the
presently disclosed method may be easily automated, making it
useful for routine diagnostic testing in a clinical laboratory
setting. With the use of RAM and HSAM, an isothermal amplification
can be achieved.
The present invention incorporates magnetic separation, utilizing
paramagnetic particles, beads or spheres that have been coated with
a ligand binding moiety that recognizes and binds to ligand present
on an oligonucleotide capture probe, described below, to isolate a
target nucleic acid (DNA or RNA) from a clinical sample in order to
facilitate its detection.
Magnetic separation is a system that uses paramagnetic particles or
beads coated with a ligand binding moiety to isolate a target
nucleic acid (RNA or DNA) (Lomeli et al. Clin. Chem. 35:1826, 1989)
from a sample, The principle underscoring this method is one of
hybrid formation between a capture probe containing a ligand, and a
target nucleic acid through the specific complementary sequence
between the probe and target. Hybridization is carried out in the
presence of a suitable chaotropic agent, e.g., guanidine
thiocyanate (GnSCN) which facilitates the specific binding of the
probe to complementary sequences in the target nucleic acid. The
hybrid so formed is then captured on the paramagnetic bead through
specific binding of the ligand on the capture probe to the ligand
binding moiety on the bead.
The term "ligand" as used herein refers to any component that has
an affinity for another component termed here as "ligand binding
moiety." The binding of the ligand to the ligand binding moiety
forms an affinity pair between the two components. For example,
such affinity pairs include, inter alia, biotin with
avidin/streptavidin, antigens or haptens with antibodies, heavy
metal derivatives with thiogroups, various polynucleotides such as
homopolynucleotides as poly dG with poly dC, poly dA with poly dT
and poly dA with poly U. Any component pairs with strong affinity
for each other can be used as the affinity pair, ligand--ligand
binding moiety. Suitable affinity pairs are also found among
ligands and conjugates used in immunological methods. The preferred
ligand-ligand binding moiety for use in the present invention is
the biotin/streptavidin affinity pair.
In one aspect, the present invention provides for the capture and
detection of a target nucleic acid as depicted in FIG. 1, which
provides a schematic depiction of the capture and detection of a
target nucleic acid. In the presence of paramagnetic beads or
particles (a) coated with a ligand binding moiety (b), the target
nucleic acid is hybridized simultaneously to a pair of
oligonucleotide amplification probes, i.e., a first nucleotide
probe (also referred to as a capture/amplification probe) and a
second nucleotide probe (also referred to as an amplification
probe), designated in FIG. 1 as Capture/Amp-probe-1 (d and e) and
Amp-probe-2 (f and g), respectively. The probes may be either
oligodeoxyribonucleotide or oligoribonucleotide molecules, with the
choice of molecule type depending on the subsequent amplification
method. Reference to "probe" herein generally refers to multiple
copies of a probe.
The capture/amplification probe is designed to have a generic 3'
nucleotide sequence (d), i.e., it is not specific for the specific
target nucleic acid being analyzed and thus can be used with a
variety of target nucleic acids. In other words, the 3' sequence of
the first probe is not complementary, nor hybridizable, to the
nucleotide sequence of the target nucleic acid. The 5' portion (e)
of the capture/amplification probe comprises a nucleotide sequence
that is complementary and hybridizable to a portion of the
nucleotide sequence of the specific target nucleic acid.
Preferably, for use with pathogenic microorganisms and viruses, the
capture/amplification probe is synthesized so that its 3' generic
sequence (d) is the same for all systems, with the 5' specific
sequence (e) being specifically complementary to a target nucleic
acid of an individual species or subspecies of organism or an
abnormal gene, e.g. the gene(s) responsible for cystic fibrosis or
sickle cell anemia. In certain instances, it may be desirable that
the 5' specific portion of the capture/amplification probe be
specifically complementary to the nucleotide sequence of a target
nucleic acid of a particular strain of organism.
Capture/Amp-probe-1 further contains a ligand (c) at the 3' end of
the probe (d), which is recognized by and binds to the ligand
binding moiety (b) coated onto the paramagnetic beads (a).
The second or amplification probe, i.e., Amp-probe-2 in FIG. 1,
contains a 3' sequence (f) that is complementary and hybridizes to
a portion of the nucleotide sequence of a target nucleic acid
immediately adjacent to (but not overlapping) the sequence of the
target that hybridizes to the 5' end of Capture/Amp-probe-1.
Amp-probe-2 also contains a 5' generic sequence (g) which is
neither complementary nor hybridizable to the target nucleic acid,
to which may be optionally attached at the 5' end thereof a label
or signal generating moiety (***). Such signal generating moieties
include, inter alia, radioisotopes, e.g., .sup.32 P or .sup.3 H,
fluorescent molecules, e.g., fluorescein and chromogenic molecules
or enzymes, e.g., peroxidase. Such labels are used for direct
detection of the target nucleic acid and detects the presence of
Amp-probe-2 bound to the target nucleic acid during the detection
step. .sup.32 P is preferred for detection analysis by radioisotope
counting or autoradiograpy of electrophoretic gels. Chromogenic
agents are preferred for detection analysis, e.g., by an enzyme
linked chromogenic assay.
As a result of the affinity of the ligand binding moiety on the
paramagnetic beads for the ligand on the capture/amplification
probe, target nucleic acid hybridized to the specific 5' portion of
the probe is captured by the paramagnetic beads. In addition,
Amp-probe-2, which has also hybridized to the target nucleic acid
is also captured by the paramagnetic beads.
After capture of the target nucleic acid and the two hybridized
probes on the paramagnetic beads, the probes are ligated together
(at the site depicted by the vertical arrow in FIG. 1) using a
ligating agent to form a contiguous single-stranded oligonucleotide
molecule, referred to herein as a ligated amplification sequence.
The ligating agent may be an enzyme, e.g., a DNA or RNA ligase, or
a chemical joining agent, e.g., cyanogen bromide or a carbodiimide
(Sokolova et al., FEBS Lett. 232:153-155, 1988). The ligated
amplification sequence is hybridized to the target nucleic acid
(either an RNA or DNA) at the region of the ligated amplification
sequence that is complementary to the target nucleic acid (e.g.,
(e) and (f) in FIG. 1).
If a sufficient amount of target nucleic acid (e.g., 10.sup.6
-10.sup.7 molecules) is present in the sample, detection of the
target nucleic acid can be achieved without any further
amplification of the ligated amplification sequence, e.g., by
detecting the presence of the optional signal generating moiety of
at the 5' end of Amp-probe-2.
If there is insufficient target nucleic acid (e.g., <10.sup.6
molecules) in the sample for direct detection, as above, the
ligated amplification sequence formed as described above by the
ligation of Capture/Amp-probe-1 and Amp-probe-2 may be amplified
for detection as described below.
Alternately, the ligated amplification sequence can be detected
without nucleic acid amplification of the ligated sequence by the
use of a hybridization signal amplification method (HSAM). HSAM is
illustrated in FIG. 10. For HSAM, the target specific nucleic acid
probe (e.g. Amp-probe-2) is internally labeled with a ligand. The
ligand is a molecule that can be bound to the nucleic acid probe,
and can provide a binding partner for a ligand binding molecule
that is at least divalent. In a preferred embodiment the ligand is
biotin or an antigen, for example digoxigenin. The nucleic acid
probe can be labeled with the ligand by methods known in the art.
In a preferred embodiment, the probe is labeled with from about 3
to about 10 molecules of ligand, preferably biotin or digoxigenin.
After the capture probe and ligand-labeled target specific probe
are added to the sample and the resulting complex is washed as
described hereinabove, the ligating agent is added to ligate the
probes as described above. The ligation of the target specific
probe to the capture probe results in retention of the target
specific probe on the beads. Concurrently or subsequently, an
excess of ligand binding moiety is added to the reaction. The
ligand binding moiety is a moiety that binds to and forms an
affinity pair with the ligand. The ligand binding moiety is at
least divalent for the ligand. In a preferred embodiment, the
ligand is biotin and the ligand binding moiety is streptavidin. In
another preferred embodiment the ligand is an antigen and the
ligand binding molecule is an antibody to the antigen. Addition of
ligating agent and ligand binding molecule results in a complex
comprising the target specific probe covalently linked to the
capture probe, with the ligand-labeled target specific probe having
ligand binding molecules bound to the ligand.
A signal probe is then added to the reaction mixture. The signal
probe is a generic nucleic acid that is internally labeled with a
ligand that binds to the ligand binding molecule. In a preferred
embodiment, the ligand is the same ligand that is used to label the
target specific amplification probe. The signal probe has a generic
sequence such that it is not complementary or hybridizable to the
target nucleic acid or the other probes. In a preferred embodiment,
the signal probe contains from about 30 to about 100 nucleotides
and contains from about 3 to about 10 molecules of ligand.
Addition of the signal probe to the complex in the presence of
excess ligand binding molecule results in the formation of a large
and easily detectable complex. The size of the complex results from
the multiple valency of the ligand binding molecule. For example,
when the ligand in the target specific amplification probe is
biotin, one molecule of streptavidin binds per molecule of biotin
in the probe. The bound streptavidin is capable of binding to three
additional molecules of biotin. When the signal probe is added, the
biotin molecules on the signal probe bind to the available binding
sites of the streptavidin bound to the amplification probe. A
web-like complex is formed as depicted schematically in FIG.
10.
Following washing as described hereinabove to remove unbound signal
probe and ligand binding molecules, the complex is then detected.
Detection of the complex is indicative of the presence of the
target nucleic acid. The HSAM method thus allows detection of the
target nucleic acid in the absence of nucleic acid
amplification.
The complex can be detected by methods known in the art and
suitable for the selected ligand and ligand binding moiety. For
example, when the ligand binding moiety is streptavidin, it can be
detected by immunoassay with streptavidin antibodies. Alternately,
the ligand binding molecule may be utilized in the present method
as a conjugate that is easily detectable. For example, the ligand
may be conjugated with a fluorochrome or with an enzyme that is
detectable by an enzyme-linked chromogenic assay, such as alkaline
phosphatase or horseradish peroxidase. For example, the ligand
binding molecule may be alkaline phosphatase-conjugated
streptavidin, which may be detected by addition of a chromogenic
alkaline phosphatase substrate, e.g. nitroblue tetrazolium
chloride.
The HSAM method may also be used with the circularizable
amplification probes described hereinbelow. The circularizable
amplification probes contain a 3' and a 5' region that are
complementary and hybridizable to adjacent but not contiguous
sequences in the target nucleic acid, and a linker region that is
not complementary nor hybridizable to the target nucleic acid. Upon
binding of the circularizable probe to the target nucleic acid, the
3' and 5' regions are juxtaposed. Linkage of the 3' and 5' regions
by addition of a linking agent results in the formation of a closed
circular molecule bound to the target nucleic acid. The
target/probe complex is then washed extensively to remove unbound
probes.
For HSAM, ligand molecules are incorporated into the linker region
of the circularizable probe, for example during probe synthesis.
The HSAM assay is then performed as described hereinabove and
depicted in FIG. 15 by adding ligand binding molecules and signal
probes to form a large complex, washing, and then detecting the
complex. Nucleic acid detection methods are known to those of
ordinary skill in the art and include, for example, latex
agglutination as described by Essers, et al. (1980). J. Clin.
Microbiol. 12:641. The use of circularizable probes in conjunction
with HSAM is particularly useful for in situ hybridization.
HSAM is also useful for detection of an antibody or antigen. A
ligand-containing antigen or antibody is used to bind to a
corresponding antibody or antigen, respectively. After washing,
excess ligand binding molecule is than added with ligand-labeled
generic nucleic acid probe. A large complex is generated and can be
detected as described hereinabove. In a preferred embodiment, the
ligand is biotin and the ligand binding molecule is streptavidin.
The use of HSAM to detect an antigen utilizing a biotinylated
antibody and biotinylated signal probe is depicted in FIG. 11.
The present methods may be used with routine clinical samples
obtained for testing purposes by a clinical diagnostic laboratory.
Clinical samples that may be used in the present methods include,
inter alia, whole blood, separated white blood cells, sputum,
urine, tissue biopsies, throat swabbings and the like, i.e., any
patient sample normally sent to a clinical laboratory for
analysis.
The present ligation-dependent amplification methods are
particularly useful for detection of target sequences in formalin
fixed, paraffin embedded (FFPE) specimens, and overcomes
deficiencies of the prior art method of reverse transcription
polymerase chain reaction (RT-PCR) for detection of target RNA
sequences in FFPE specimens. RT-PCR has a variable detection
sensitivity, presumably because the formation of RNA--RNA and
RNA-protein crosslinks during formalin fixation prevents reverse
transcriptase from extending the primers. In the present methods
the probes can hybridize to the targets despite the crosslinks,
reverse transcription is not required, and the probe, rather than
the target sequence, is amplified. Thus the sensitivity of the
present methods is not comprised by the presence of crosslinks. The
advantages of the present methods relative to RT-PCR are depicted
schematically in FIG. 12.
With reference to FIG. 2, which provides a general diagrammatic
description of the magnetic separation and target-dependent
detection of a target nucleic acid in a sample, this aspect of the
present method involves the following steps: (a) The first step is
the capture or isolation of a target nucleic acid present in the
sample being analyzed, e.g., serum. A suitable sample size for
analysis that lends itself well to being performed in a micro-well
plate is about 100 .mu.l. The use of micro-well plates for analysis
of samples by the present method facilitates automation of the
method. The sample, containing a suspected pathogenic microorganism
or virus or abnormal gene, is incubated with an equal volume of
lysis buffer, containing a chaotropic agent (i.e., an agent that
disrupts hydrogen bonds in a compound), a stabilizer and a
detergent, which provides for the release of any nucleic acids and
proteins that are present in the sample. For example, a suitable
lysis buffer for use in the present method comprises 2.5-5M
guanidine thiocyanate (GnSCN), 10% dextran sulfate, 100 mM EDTA,
200 mM Tris-HCl(pH 8.0) and 0.5% NP-40 (Nonidet P-40, a nonionic
detergent, N-lauroylsarcosine, Sigma Chemical Co., St. Louis, Mo.).
The concentration of GnSCN, which is a chaotropic agent, in the
buffer also has the effect of denaturing proteins and other
molecules involved in pathogenicity of the microorganism or virus.
This aids in preventing the possibility of any accidental infection
that may occur during subsequent manipulations of samples
containing pathogens.
Paramagnetic particles or beads coated with the ligand binding
moiety are added to the sample, either simultaneous with or prior
to treatment with the lysis buffer. The paramagnetic beads or
particles used in the present method comprise ferricoxide particles
(generally <1 um in diameter) that possess highly convoluted
surfaces coated with silicon hydrides. The ligand binding moiety is
covalently linked to the silicon hydrides. The paramagnetic
particles or beads are not magnetic themselves and do not aggregate
together. However, when placed in a magnetic field, they are
attracted to the magnetic source. Accordingly, the paramagnetic
particles or beads, together with anything bound to them, may be
separated from other components of a mixture by placing the
reaction vessel in the presence of a strong magnetic field provided
by a magnetic separation device. Such devices are commercially
available, e.g., from Promega Corporation or Stratagene, Inc.
Suitable paramagnetic beads for use in the present method are those
coated with streptavidin, which binds to biotin. Such beads are
commercially available from several sources, e.g., Streptavidin
MagneSphere.RTM. paramagnetic particles obtainable from Promega
Corporation and Streptavidin-Magnetic Beads (catalog #MB002)
obtainable from American Qualex, La Mirada, Calif.
Subsequently, a pair of oligonucleotide amplification probes, as
described above, is added to the lysed sample and paramagnetic
beads. In a variation, the probes and paramagnetic beads may be
added at the same time. As described above, the two oligonucleotide
probes are a first probe or capture/amplification probe (designated
Capture/Amp-probe-1 in FIG. 1) containing a ligand at its 3' end
and a second probe or amplification probe (designated Amp-probe-2
in FIG. 1). For use with streptavidin-coated paramagnetic beads,
the first probe is preferably a 3'-biotinylated
capture/amplification probe.
The probes may be synthesized from nucleoside triphosphates by
known automated oligonucleotide synthetic techniques, e.g., via
standard phosphoramidite technology utilizing a nucleic acid
synthesizer. Such synthesizers are available, e.g., from Applied
Biosystems, Inc. (Foster City, Calif.).
Each of the oligonucleotide probes are about 40-200 nucleotides in
length, preferably about 50-100 nucleotides in length, which, after
ligation of the probes, provides a ligated amplification sequence
of about 80-400, preferably 100-200, nucleotides in length, which
is suitable for amplification via PCR, Q.beta. replicase or SDA
reactions.
The target nucleic acid specific portions of the probes, i.e., the
5' end of the first capture/amplification probe and the 3' end of
the second amplification probe complementary to the nucleotide
sequence of the target nucleic acid, are each approximately 15-60
nucleotides in length, preferably about 18-35 nucleotides, which
provides a sufficient length for adequate hybridization of the
probes to the target nucleic acid.
With regard to the generic portions of the probes, i.e., the 3' end
of the capture/amplification probe and the 5' end of the
amplification probe, which are not complementary to the target
nucleic acid, the following considerations, inter alia, apply: (1)
The generic nucleotide sequence of an oligodeoxy-nucleotide
capture/amplification probe comprises at least one and, preferably
two to four, restriction endonuclease recognition sequences(s) of
about six nucleotides in length, which can be utilized, if desired,
to cleave the ligated amplification sequence from the paramagnetic
beads by specific restriction endonucleases, as discussed below.
Preferred restriction sites include, inter alia, EcoRI (GAATTC),
SmaI (CCCGGG) and HindIII (AAGCTT). (2) The generic nucleotide
sequence comprises a G-C rich region which, upon hybridization to a
primer, as discussed below, provides a more stable duplex molecule,
e.g., one which requires a higher temperature to denature. Ligated
amplification sequences having G-C rich generic portions of the
capture/amplification and amplification probes may be amplified
using a two temperature PCR reaction, wherein primer hybridization
and extension may both be carried out at a temperature of about
60.degree.-65.degree. C. (as opposed to hybridizing at 37.degree.
C., normally used for PCR amplification) and denaturation at a
temperature of about 92.degree. C., as discussed below. The use of
a two temperature reaction reduces the length of each PCR
amplification cycle and results in a shorter assay time.
Following incubation of the probes, magnetic beads and target
nucleic acid in the lysis buffer for about 30-60 minutes, at a
temperature of about 37.degree. C., a ternary complex comprising
the target nucleic acid and hybridized probes is formed, which is
bound to the paramagnetic beads through the binding of the ligand
(e.g., biotin) on the capture/amplification probe to the ligand
binding moiety (e.g., streptavidin) on the paramagnetic beads. The
method is carried out as follows: (a) The complex comprising target
nucleic acid-probes-beads is then separated from the lysis buffer
by means of a magnetic field generated by a magnetic device, which
attracts the beads. The magnetic field is used to hold the complex
to the walls of the reaction vessel, e.g., a micro-well plate or a
microtube, thereby allowing for the lysis buffer and any unbound
reactants to be removed, e.g., by decanting, without any
appreciable loss of target nucleic acid or hybridized probes. The
complex is then washed 2-3 times in the presence of the magnetic
field with a buffer that contains a chaotropic agent and detergent
in amounts that will not dissociate the complex. A suitable washing
buffer for use in the present method comprises about 1.0-1.5M
GnSCN, 10 mM EDTA, 100 mM Tris-HCl (pH 8.0) and 0.5% NP-40 (Nonidet
P-40, nonionic detergent, Sigma Chemical Co., St. Louis, Mo.).
Other nonionic detergents, e.g., Triton X-100, may also be used.
The buffer wash removes unbound proteins, nucleic acids and probes
that may interfere with subsequent steps. The washed complex may be
then washed with a solution of KCl to remove the GnSCN and
detergent and to preserve the complex. A suitable concentration of
KCl is about 100 to 500 mM KCl. Alternatively, the KCl wash step
may be omitted in favor of two washes with ligase buffer. (b) If
the probes to be ligated together, the next step in the present
method involves treating the complex from step (a) with a ligating
agent that will join the two probes. The ligating agent may be an
enzyme, e.g., DNA or RNA ligase, or a chemical agent, e.g.,
cyanogen bromide or a carbodiimide. This serves to join the 5' end
of the first oligonucleotide probe to the 3' end of the second
oligonucleotide probe (capture/amplification probe and
amplification probe, respectively) to form a contiguous functional
single-stranded oligonucleotide molecule, referred to herein as a
ligated amplification sequence. The presence of the ligated
amplification sequence detected, (via the signal generating moiety
at the 5'-end of Amp-probe-2), indirectly indicates the presence of
target nucleic acid in the sample. Alternatively, the ligated
amplification sequence serves as the template for any of various
amplification systems, such as PCR or SDA. Any of the first and
second probes which remain unligated after treatment are not
amplified in subsequent steps in the method. Capture/amplification
and amplification oligodeoxy-nucleotide probes may be ligated using
a suitable ligating agent, such as a DNA or RNA ligase.
Alternatively, the ligating agent may be a chemical, such as
cyanogen bromide or a carbodiimide (Sokolova et al., FEBS Lett.
232:153-155, 1988). Preferred DNA ligases include T.sub.4 DNA
ligase and the thermostable Taq DNA ligase, with the latter being
most preferable, for probes being subjected to amplification using
PCR techniques. The advantage of using the Taq DNA ligase is that
it is active at elevated temperatures (65.degree.-72.degree. C.).
Joining the oligonucleotide probes at such elevated temperatures
decreases non-specific ligation. Preferably, the ligation step is
carried out for 30-60 minutes at an elevated temperature (about
65-72.degree. C.), after which time any unligated second
amplification probe (Amp-probe-2 in FIG. 1) may be, optionally,
removed under denaturing conditions.
Denaturation is performed after the ligation step by adding TE
Buffer (10 mM Tris-HCl pH 7.5, 0.1 mM EDTA) to the mixture. The
temperature of the mixture is then raised to about 92-95.degree. C.
for about 1-5 minutes to denature the hybridized nucleic acid. This
treatment separates the target nucleic acid (and unligated
Amp-probe-2) from the hybridized ligated amplification sequences,
which remains bound to the paramagnetic beads. In the presence of a
magnetic field, as above, the bound ligated amplification sequence
is washed with TE Buffer at elevated temperature to remove
denatured target nucleic acid and any unligated Amp-probe-2 and
resuspended in TE Buffer for further analysis. (c) The third step
in the process is detection of the ligated amplification sequence,
which indicates the presence of the target nucleic acid in the
original test sample. This may be performed directly if sufficient
target nucleic acid (about 10.sup.6 -10.sup.7 molecules) is present
in the sample or following amplification of the ligated
amplification sequence, using one of the various amplification
techniques, e.g., PCR or SDA. For example, direct detection may be
used to detect HIV-1 RNA in a serum sample from an acutely infected
AIDS patient. Such a serum sample is believed to contain about
10.sup.6 copies of the viral RNA/ml.
For direct detection, an oligonucleotide detection probe of
approximately 10-15 nucleotides, in length, prepared by automotive
synthesis as described above to be complementary to the 5' end of
the Amp-probe-2 portion of the ligated amplification sequence, may
be added to the ligated amplification sequence attached to the
paramagnetic beads. The detection probe, which is labelled with a
signal generating moiety, e.g., a radioisotope, a chromogenic agent
or a fluorescent agent, is incubated with the complex for a period
of time and under conditions sufficient to allow the detection
probe to hybridize to the ligated amplification sequence. The
incubation time can range from about 1-60 minutes and may be
carried out at a temperature of about 4-60.degree. C. Preferably,
when the label is a flurogenic agent, the incubation temperature is
about 4.degree. C.; a chromogenic agent, about 37.degree. C.; and a
radioisotope, about 37.degree.14 60.degree. C. Preferred signal
generating moieties include, inter alia, .sup.32 P (radioisotope),
peroxidase (chromogenic) and fluorescein, acridine or ethidium
(fluorescent).
Alternatively, for direct detection, as discussed above, the
Amp-probe-2 itself may be optionally labeled at its 5' end with a
signal generating moiety, e.g., .sup.32 P. The signal generating
moiety will then be incorporated into the ligated amplification
sequence following ligation of the Capture/Amp-probe-1 and
Amp-probe-2. Thus, direct detection of the ligated amplification
sequence, to indicate the presence of the target nucleic acid, can
be carried out immediately following ligation and washing.
Any suitable technique for detecting the signal generating moiety
directly on the ligated amplification probe or hybridized thereto
via the detection primer may be utilized. Such techniques include
scintillation counting (for .sup.32 P) and chromogenic or
fluorogenic detection methods as known in the art. For example,
suitable detection methods may be found, inter alia, in Sambrook et
al., Molecular Cloning--A Laboratory Manual, 2d Edit., Cold Spring
Harbor Laboratory, 1989, in Methods in Enzymology, Volume 152,
Academic Press (1987) or Wu et al., Recombinant DNA Methodology,
Academic Press (1989).
If an insufficient amount of target nucleic acid is present in the
original sample (<10.sup.6 molecules), an amplification system
is used to amplify the ligated amplification sequence for
detection.
For example, if the probes used in the present method are
oligodeoxyribonucleotide molecules, PCR methodology can be employed
to amplify the ligated amplification sequence, using known
techniques (see, e.g., PCR Technology, H. A. Erlich, ed., Stockton
Press, 1989, Sambrook et al., Molecular Cloning--A Laboratory
Manual, 2d Edit., Cold Spring Harbor Laboratory, 1989. When using
PCR for amplification, two primers are employed, the first of the
primers being complementary to the generic 3' end of
Capture/Amp-probe-1 region of the ligated amplification sequence
and the second primer corresponding in sequence to the generic 5'
end of Amp-probe-2 portion of the ligated amplification sequence.
These primers, like the sequences of the probes to which they bind,
are designed to be generic and may be used in all assays,
irrespective of the sequence of the target nucleic acid. Because
the first primer is designed to anneal to the generic sequence at
the 3' end of the ligated amplification sequence and the second
primer corresponds in sequence to the generic sequence at the 5'
end of the ligated amplification sequence, generic primers may be
utilized to amplify any ligated amplification sequence.
A generic pair of PCR oligonucleotide primers for use in the
present method may be synthesized from nucleoside triphosphates by
known automated synthetic techniques, as discussed above for
synthesis of the oligonucleotide probes. The primers may be 10-60
nucleotides in length. Preferably the oligonucleotide primers are
about 18-35 nucleotides in length, with lengths of 16-21
nucleotides being most preferred. The pair of primers are
designated to be complementary to the generic portions of the first
capture/amplification probe and second amplification probe,
respectively and thus have high G-C content. It is also preferred
that the primers are designed so that they do not have any
secondary structure, i.e., each primer contains no complementary
region within itself that could lead to self annealing.
The high G-C content of the generic PCR primers and the generic
portions of the ligated amplification sequence permits performing
the PCR reaction at two temperatures, rather than the usual three
temperature method. Generally, in the three temperature method,
each cycle of amplification is carried out as follows: Annealing of
the primers to the ligated amplification sequence is carried out at
about 37.degree.-50.degree. C.; extension of the primer sequence by
Taq polymerase in the presence of nucleoside triphosphates is
carried out at about 70.degree.-75.degree. C.; and the denaturing
step to release the extended primer is carried out at about
90.degree.-95.degree. C. In the two temperature PCR technique, the
annealing and extension steps may both be carried at about
60.degree.-65.degree. C., thus reducing the length of each
amplification cycle and resulting in a shorter assay time.
For example, a suitable three temperature PCR amplification (as
provided in Saiki et al., Science 239:487-491, 1988) may be carried
out as follows: Polymerase chain reactions (PCR) are carried out in
about 25-50 .mu.l samples containing 0.01 to 1.0 ng of template
ligated amplification sequence, 10 to 100 pmol of each generic
primer, 1.5 units of Taq DNA polymerase (Promega Corp.), 0.2 mM
DATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM dTTP, 15 mM MgCl.sub.2, 10
mM Tris-HCl(pH 9.0), 50 mM KCl, 1 .mu.g/ml gelatin, and 10 .mu.l/ml
Triton X-100 (Saiki, 1988). Reactions are incubated at 92.degree.
C. for 1 minute, about 37.degree. C. to 55.degree. C. for 2 minutes
(depending on the identity of the primers), and about 72.degree. C.
for 3 minutes and repeated for 30-40, preferably 35, cycles. A 4
.mu.l-aliquot of each reaction is analyzed by electrophoresis
through a 2% agarose gel and the DNA products in the sample are
visualized by staining the gel with ethidium-bromide.
The two temperature PCR technique, as discussed above, differs from
the above only in carrying out the annealing/extension steps at a
single temperature, e.g., about 60.degree.-65.degree. C. for about
5 minutes, rather than at two temperatures.
Also, with reference to FIG. 2, quantitative detection of the
target nucleic acid using a competitive PCR assay may also be
carried out. For such quantitative detection, a
oligodeoxyribonucleotide releasing primer, synthesized generally as
described above, is added to the paramagnetic bead-bound ligated
amplification sequence. The releasing primer, may or may not be
but, preferably, will be the same as the first PCR primer discussed
above. The releasing primer is designed to hybridize to the generic
3' end of the Capture/Amp-probe-1 portion of the ligated
amplification sequence, which, as discussed above, comprises a
nucleotide sequence recognized by at least one, and preferably
two-four, restriction endonucleases to form at least one, and
preferably two-four, double-stranded restriction enzyme cleavage
site, e.g., a EcoRI, SmaI and/or HindIII site(s).
In this regard, as noted above, for use in a quantitative PCR
amplification and detections system, it is important that the
Capture/Amp-probe-1 be synthesized with at least one, and
preferably two to four nucleotide sequences recognized by a
restriction enzyme located at the 3' end of the probe. This
provides the nucleotide sequences to which the releasing primer
binds to form double-stranded restriction enzyme cleavage
site(s).
After ligating the first and second probes to form the ligated
amplification sequence, the releasing primer is hybridized to the
ligated amplification sequence. At least one restriction enzyme,
e.g., EcoRI, SmaI and/or HindIII, is then added to the hybridized
primer and ligated amplification sequence. The ligated
amplification sequence is released from the beads by cleavage at
the restriction enzyme, e.g., EcoRI site.
Following its release from the beads, the ligated amplification
sequence is serially diluted and then quantitatively amplified via
the DNA Tag polymerase using a suitable PCR amplification
technique, as described above.
Quantitation of the original target nucleic acid in the sample may
be performed by a competitive PCR method to quantitatively amplify
the ligated amplification sequence, as provided, e.g., in Sambrook
et al., Molecular Cloning--A Laboratory Manual, 2d Edit., Cold
Spring Harbor Laboratory, 1989.
In general, the method involves coamplification of two templates:
the ligated amplification sequence and a control (e.g., the generic
portions of the ligated amplification sequence or the generic
portions that have interposed thereto a nucleotide sequence
unrelated to the sequence of the target nucleic acid) added in
known amounts to a series of amplification reactions. While the
control and ligated amplification sequence are amplified by the
same pair of generic PCR primers, the control template is
distinguishable from the ligated amplification sequence, e.g., by
being different in size. Because the control and ligated
amplification sequence templates are present in the same
amplification reaction and use the same primers, the effect of a
number of variables which can effect the efficiency of the
amplification reaction is essentially nullified. Such variables
included, inter alia: (1) quality and concentration of reagents
(Taq DNA polymerase, primers, templates, dNTP's). (2) conditions
used for denaturation, annealing and primer extension. (3) rate of
change of reaction temperature and (4) priming efficiency of the
oligonucleotide primers. The relative amounts of two amplified
products--i.e., ligated amplification sequence and control
template--reflect the relative concentrations of the starting
templates.
The quantitative PCR method may be generally carried out as
follows: 1. A control template, e.g., a DNA sequence corresponding
to a nanovariant RNA, a naturally occurring template of Q.beta.
replicase (Schaffner et al., J. Mol. Biol. 117:877-907, 1977) is
synthesized by automated oligonucleotide synthesis and its
concentration determined, e.g., by spectrophotometry or by
ethidium-bromide mediated fluorescence. 2. A series of tenfold
dilutions (in TE Buffer) containing from 10 ng/ml to 1 fg/ml of the
control template is made and stored at -70.degree. C. until use. 3.
A series of PCR amplification reactions of the free ligated
amplification sequence is set up. In addition to the usual PCR
ingredients, the reactions also contain about 10 .mu.l/reaction of
the tenfold dilutions of the control template and about 10
.mu.Ci/reaction of [.alpha..sup.32 P] dCTP(Sp.act. 3000 Ci/mmole).
4. PCR amplification reactions are carried out for a desired number
of cycles, e.g., 30-40. 5. The reaction products may then be
subject to agarose gel electrophoresis and autoradiography to
separate the two amplified products (of different sizes). The
amplified bands of the control and ligated amplification sequence
are recovered from the gel using suitable techniques and
radioactivity present in each band is determined by counting in a
scintillation counter. The relative amounts of the two products are
calculated based on the amount of radioactivity in each band. The
amount of radioactivity in the two samples must be corrected for
the differences in molecular weights of the two products. 6. The
reactions may be repeated using a narrower range of concentrations
of control template to better estimate the concentrations of
ligated amplification sequence.
In another aspect of the invention, more than the two probes i.e. a
single capture/amplification probe, and a single amplification
probe may be utilized. For example one or more
capture/amplification probes, and one or more amplification probes,
may be employed in the detection and capture of the target nucleic
acid, and optional amplification of the target sequences, as shown
schematically in FIGS. 4 and 5. According to this aspect of the
present invention, the capture/amplification probes may have a 3'
sequence complementary to the target nucleic acid and a biotin
moiety at the 5' terminus that is capable of interacting with the
streptavidin coated paramagnetic beads. Alternatively, the
capture/amplification probes may have a 5' sequence complementary
to the target nucleic acid and a biotin moiety at the 3'
terminus.
Further, according to this aspect of the present invention, one or
more amplification probes are utilized such that each probe
contains sequences that are specifically complementary to and
hybridizable with the target nucleic acid. For example, the 5' end
of one amplification probe, e.g. Amp-probe-2 (HCV A) in FIG. 4,
contains a sequence complementary to a distinct portion in the
target nucleic acid. The 3' end of the second amplifications probe
e.g. Amp-probe-2A (HCV A) in FIG. 4, contains a specific sequence
complementary to a region of the target nucleic acid that is
immediately adjacent to that portion of the target hybridizable to
the first amplification probe. The capture/amplification probes and
the pair of amplification probes hybridize with the target nucleic
acid in the presence of GnSCN as described above. This complex so
formed is bound to streptavidin-coated paramagnetic beads by means
of a biotin moiety on the capture/amplification probes and the
complex separated from unreacted components by means of magnetic
separation as above. Next, the amplification probes may be linked,
for example, by a ligase enzyme. This produces a ligated
amplification sequence that serves as a template for Tag DNA
polymerase during amplification reaction by PCR.
In a particular aspect of the invention, two or more
capture/amplification probes and two pairs of amplification probes
are utilized for the detections of the target nucleic acid.
The use of multiple capture/amplification probes affords even
better capture efficiency, permitting the capture of multiple
targets with generic capture probes. This is especially desirable
for multiplex PCR reactions where multiple targets within a single
reaction may be detected.
For example, a capture/amplification probe for use in the present
method may be designed to bind to the poly-A tail region of
cellular mRNA, whereby all such mRNA can be isolated by a single
capture-and-wash step. Subsequent PCR amplification may be designed
to detect and amplify specific target pathogen or disease gene
sequences from such an mRNA pool. Such genes may include, inter
alia, the gene encoding the cystic fibrosis transmembrane regulator
protein (CFTR) or hemoglobins or other proteins involved in genetic
diseases.
In still another aspect of the invention, the multiple
capture/amplification probes may target, for example, all strains
of a particular pathogen, e.g. the Hepatitis C Virus (HCV), and
amplification probes may be tailored to detect and further identify
individual HCV genotypes of the pathogen (e.g. HCV).
In a further embodiment, two capture/amplification probes are
utilized, e.g. as depicted in FIG. 4. This provides a total
specific sequence of the capture/amplification probes complementary
and hybridizable to the target nucleic acid that can be twice as
long as that of a single capture/amplification probe, thereby
affording an even higher capture efficiency.
The pair of capture/amplification probes, e.g. as shown in FIG. 4,
may each have a 3' sequence complementary to the target nucleic
acid, and a biotin moiety at its 5' terminus capable of interacting
with streptavidin coated paramagnetic beads. Alternatively, the
pair of capture/amplifications probes may each have a 5' sequence
complementary to the target nucleic acid, and a biotin moiety at
its 3' terminus capable of interacting with streptavidin coated
paramagnetic beads.
Further, the present method in which the ligated target probe is
amplified by PCR permits the detection of multiple targets in a
single reaction, as illustrated in FIG. 13 and designated as
multiplex LD-PCR. In the prior art methods of PCR amplification of
a target nucleic acid, attempts to detect multiple targets with
multiple primer pairs in a single reaction vessel have been limited
by varying primer efficiencies and competition among primer pairs.
In contrast, in the present method each capture/amplification probe
has a target specific region and a generic region. In multiplex
LD-PCR according to the present invention, the generic regions to
which the PCR primers bind may be common to all
capture/amplification probes. Thus multiple pairs of
capture/amplification probes having specificity for multiple
targets may be used, but only one pair of generic PCR primers are
needed to amplify the ligated capture/amplification probes. By
varying the length of the target specific regions of the
capture/amplification probes, amplified PCR products corresponding
to a particular target can be identified by size.
The PCR products may also be identified by an enzyme-linked
immunosorbent assay (ELISA). The PCR product may be labeled during
amplification with an antigen, for example digoxigenin. The labeled
PCR product is then captured on a microtiter plate having thereon a
nucleic acid probe that hybridizes to the target specific region of
the amplification probe, which region is present in the amplified
product. The labeled captured product may then be detected by
adding an enzyme conjugated antibody against the antigen label, for
example horseradish peroxidase anti-digoxigenin antibody, and a
color indicator to each well of the microtiter plate. The optical
density of each well provides a measure of the amount of PCR
product, which in turn indicates the presence of the target nucleic
acid in the original sample.
In still further embodiments, the present invention may utilize a
single amplifiable "full length probe" and one or more
capture/amplification probes as shown in FIG. 6. Further, the
hybridized nucleic acid duplex, comprising of the target nucleic
acid, for example, HCV RNA, and the capture/amplification probes
and full length amplification probes, also referred to as
amplification sequences, can be released from the magnetic beads by
treating the hybridized duplex molecule with RNAase H.
Alternatively, the hybridized duplex, comprising of the target
nucleic acid, e.g. DNA, and the capture/amplification probes and
full length amplification probes, can be released from the magnetic
beads by treating the hybridized duplex molecule with appropriate
restriction enzymes, as described above.
When a full length amplification probe is employed to detect a
target nucleic acid sequence, the probe may be utilized in
amplification reactions such as PCR, without having to use the
ligation step described above. This latter approach, in particular,
simplifies the assay and is especially useful when at least
10.sup.4 target nucleic acid molecules are available in the testing
sample, so that the chances of non-specific binding in a ligation
independent detection reaction are reduced. In most clinical
detection assays, the target nucleic acid (such as a pathogen), is
present at >10.sup.5 molecules/ml. of sample, and thus would be
amenable to detection and amplifications by this method.
A still further aspect of the present invention utilizes one or
more capture/amplification probes, each containing a biotin moiety,
and a single amplification probe, also referred to as an
amplification sequence, that hybridizes to the target nucleic acid
and circularizes upon ligation of its free termini, as shown in
FIG. 7. The amplification probe may be designed so that
complementary regions (see e.g. the region shown in bold in FIG. 7)
of the probe that are hybridizable to the target nucleic acid
sequence are located at each end of the probe (as described in
Nilsson et al., 1994, Science 165:2085-2088). When the probe
hybridizes with the target, its termini are placed adjacent to each
other, resulting in the formation of a closed circular molecule
upon ligation with a linking agent such as a ligase enzyme. This
circular molecule may then serve as a template during an
amplification step, e.g. PCR, using primers such as those depicted
in FIG. 7. The circular molecule may also be amplified by RAM, as
described hereinbelow, or detected by a modified HSAM assay, as
described hereinbelow.
For example, the probe, described above, can be used to detect
different genotypes of pathogen, e.g. different genotypes of HCV
from serum specimens. Genotype specific probes can be designed,
based on published HCV sequences (Stuyver et al., 1993, J. Gen.
Virol. 74;1093-1102), such that a mutation in the target nucleic
acid is detectable since such a mutation would interfere with (1)
proper hybridization of the probe to the target nucleic acid and
(2) subsequent ligation of the probe into a circular molecule.
Because of the nature of the circularized probe, as discussed
below, unligated probes may be removed under stringent washing
conditions.
The single, full length, ligation-dependent circularizable probe,
as utilized in the method, affords greater efficiency of the
detection and amplification of the target nucleic acid sequence.
Due to the helical nature of double-stranded nucleic acid
molecules, circularized probes are wound around the target nucleic
acid strand. As a result of the ligation step, the probe may be
covalently bound to the target molecule by means of catenation.
This results in immobilization of the probe on the target molecule,
forming a hybrid molecule that is substantially resistant to
stringent washing conditions. This results in significant reduction
of non-specific signals during the assay, lower background noise
and an increase in the specificity of the assay.
Another embodiment of the present invention provides a method of
reducing carryover contamination an background in amplification
methods utilizing circular probes. The present ligation-dependent
amplification methods, unlike conventional amplification methods,
involve amplification of the ligated probe(s) rather than the
target nucleic acid. When the ligated probe is a closed circular
molecule, it has no free ends susceptible to exonuclease digestion.
After probe ligation, i.e. circularization, treatment of the
reaction mixture with an exonuclease provides a "clean-up" step and
thus reduces background and carryover contamination by digesting
unligated probes of linear DNA fragments but not closed circular
molecules. The covalently linked circular molecules remain intact
for subsequent amplification and detection. In conventional PCR,
the use of exonuclease to eliminate single stranded primers or
carryover DNA fragments poses the risk that target nucleic acid
will also be degraded. The present invention does not suffer this
risk because target nucleic acid is not amplified. In a preferred
embodiment, the exonuclease is exonuclease III, exonuclease VII,
mung bean nuclease or nuclease BAL-31. Exonuclease is added to the
reaction after ligation and prior to amplification, and incubated,
for example at 37.degree. C. for thirty minutes.
It is further contemplated to use multiple probes which can be
ligated to form a single covalently closed circular probe. For
example, a first probe is selected to hybridize to a region of the
target. A second probe is selected such that its 3' and 5' termini
hybridize to regions of the target that are adjacent but not
contiguous with the 5' and 3' termini of the first probe. Two
ligation events are then required to provide a covalently closed
circular probe. By using two ligases, e.g. an enzymatic and a
chemical ligase, to covalently close the probe, the order of the
ligations can be controlled. This embodiment is particularly useful
to identify two nearby mutations in a single target.
The circularized probe can also be amplified and detected by the
generation of a large polymer. The polymer is generated through the
rolling circle extension of primer 1 along the circularized probe
and a displacement of downstream sequence. This step produces a
single stranded DNA containing multiple units which serves as a
template for subsequent PCR, as depicted in FIGS. 9 and 16. As
shown therein, primer 2 can bind to the single stranded DNA polymer
and extend simultaneously, resulting in displacement of downstream
primers by upstream primers. By using both
primer-extension/displacement and PCR, more detectable product is
produced with the same number of cycles.
The circularized probe may also be detected by a modification of
the HSAM assay. In this method, depicted in FIG. 14, the
circularizable amplification probe contains, as described
hereinabove, 3'- and 5' regions that are complementary to adjacent
regions of the target nucleic acid. The circularizable probes
further contain a non-complementary, or generic linker region. In
the present signal amplification method, the linker region of the
circularizable probe contains at least one pair of adjacent regions
that are complementary to the 3' and 5' regions of a first generic
circularizable signal probe (CS-probe). The first CS-probe
contains, in its 3' and 5' regions, sequences that are
complementary to the adjacent regions of the linker region of the
circularizable amplification probe. Binding of the circularizable
amplification probe to the target nucleic acid, followed by
ligation, results in a covalently linked circular probe having a
region in the linker available for binding to the 3' and 5' ends of
a first CS-probe. The addition of the first CS-probe results in
binding of its 3' and 5' regions to the complementary regions of
the linker of the circular amplification probe. The 3' and 5'
regions of the CS-probe are joined by the ligating agent to form a
closed circular CS-probe bound to the closed circular amplification
probe. The first CS-probe further contains a linker region
containing at least one pair of adjacent contiguous regions
designed to be complementary to the 3' and 5' regions of a second
CS-probe.
The second CS-probe contains, in its 3' and 5' regions, sequences
that are complementary to the adjacent regions of the linker region
of the first CS-probe. The addition of the second CS-probe results
in binding of its 3' and 5' regions to the complementary regions of
the linker of the first CS-probe. The 3' and 5' regions of the
second CS-probe are joined by the ligating agent to form a closed
circular CS-probe, which is in turn bound to the closed circular
amplification probe.
By forming the above-described method with a multiplicity of
CS-probes having multiple pairs of complementary regions, a large
cluster of chained molecules is formed on the target nucleic acid.
In a preferred embodiment, three CS-probes are utilized. In
addition to the 3' and 5' regions, each of the CS-probes has one
pair of complementary regions that are complementary to the 3' and
5' regions of a second CS-probe, and another pair of complementary
regions that are complementary to the 3' and 5' regions of the
third CS-probe. By utilizing these "trivalent" CS-probes in the
method of the invention, a cluster of chained molecules as depicted
in FIG. 14 is produced.
Following extensive washing to remove non-specific chain reactions
that are unlinked to the target, the target nucleic acid is then
detected by detecting the cluster of chained molecules. The chained
molecules can be easily detected by digesting the complex with a
restriction endonuclease for which the recognition sequence has
been uniquely incorporated into the linker region of each CS-probe.
Restriction endonuclease digestion results in a linearized monomer
that can be visualized on a polyacrylamide gel. Other methods of
detection can be effected by incorporating a detectable molecule
into the CS-probe., for example digoxigenin, biotin, or a
fluorescent molecule, and detecting with anti-digoxinin,
streptavidin, or fluorescence detection. Latex agglutination, as
described for example by Essers et al. (1980) J. Clin. Microbiol.
12, 641, may also be used. Such nucleic acid detection methods are
known to one of ordinary skill in the art.
Moreover, in a special application, the amplification probes and/or
amplification sequences as described above, can be used for in situ
LD-PCR assays. In situ PCR may be utilized for the direct
localization and visualization of target viral nucleic acids and
may be further useful in correlating viral infection with
histopathological finding.
Current methods assaying for target viral RNA sequences have
utilized RT PCR techniques for this purpose (Nuovo et al., 1993,
Am. J. Surg. Pathol. 17(7):683-690). In this method cDNA, obtained
from target viral RNA by in situ reverse transcription, is
amplified by the PCR method. Subsequent intracellular localization
of the amplified cDNA can be accomplished by in situ hybridization
of the amplified cDNA with a labelled probe or by the incorporation
of labelled nucleotide into the DNA during the amplification
reaction.
However, the RT PCR method suffers drawbacks which are overcome by
the present invention. For example, various tissue fixatives used
to treat sample tissues effect the crosslinking of cellular nucleic
acids and proteins, e.g. protein-RNA and RNA--RNA complexes and
hinder reverse transcription, a key step in RT-PCR. Moreover,
secondary structures in target RNA may also interfere with reverse
transcription. Further, the application of multiplex PCR to RT PCR
for the detection of multiple target sequences in a single cell can
present significant problems due to the different efficiencies of
each primer pair.
The method of the present invention utilizes one or more
amplification probes and/or amplification sequences, as described
above, and the LD-PCR technique to locate and detect in situ target
nucleic acid, which offers certain advantages over the RT-PCR
method. First, since hybridization of the probe to target nucleic
acid and subsequent amplification of the probe sequences eleminates
the reverse transcription step of the RT-PCR method, the secondary
structure of the target RNA does not affect the outcome of the
assay. Moreover, the crosslinking of target nucleic acids and
cellular proteins due to tissue fixatives, as discussed above, does
not interfere with the amplification of probe sequences since there
is no primer extension of the target RNA as in the RT-PCR
method.
In particular, amplification probes according to the present
invention may be designed such that there are common primer-binding
sequences within probes detecting different genotypic variants of a
target pathogen. This enables the assay to detect multiple targets
in a single sample. For example, and not by way of limitation, the
assay may utilize two or more amplification probes according to
this method to detect HCV RNA and .beta.-actin RNA, whereby the
.beta.-actin probe serves as an internal control for the assay.
Furthermore, the primer-binding sequences in the probe may be
designed to (1) minimize non-specific primer oligomerization and
(2) achieve superior primer-binding and increased yield of PCR
products, thereby increasing sensitivity of the assay.
Since the amplification probe circularizes after binding to target
nucleic acid to become a circular molecule, multimeric products may
be generated during polymerization, so that amplification products
are easily detectable, as described above, as shown in FIGS. 9 and
16.
As in situ LD-PCR assay to detect target nucleic acids in
histological specimens according to the present invention utilizes
a ligation dependent full length amplification probe, and involves
the following steps: Sample tissue, e.g. liver, that may be frozen,
or formalin-fixed and embedded in paraffin, is sectioned and placed
on silane-coated slides. The sections may be washed with xylene and
ethanol to remove the paraffin. The sections may then be treated
with a proteolytic enzyme, such as trypsin, to increase membrane
permeability. The sections may be further treated with RNAase-free
DNAase to eliminate cellular DNA.
An amplification probe may be suspended in a suitable buffer and
added to the sample sections on the slide and allowed to hybridize
with the target sequences. Preferably, the probe may dissolved in
2.times.SSC with 20% formamide, added to the slide, and the mixture
incubated for 2 hours at 37.degree. C., for hybridization to occur.
The slide may be washed once with 2.times.SSC and twice with
1.times.ligase buffer before DNA ligase may be applied to the
sample. Preferably, 1 U/20 .mu.l of the ligase enzyme may be added
to each slide, and the mixture incubated at 37.degree. C. for 2
hours to allow circularization of the probe. The slide may be
washed with 0.2.times.SSC (high stringency buffer) and 1.times.PCR
buffer to remove unligated probes before the next step of
amplification by PCR. The PCR reaction mixture, containing the
amplification primers and one or more labelled nucleotides is now
added to the sample on the slide for the amplification of the
target sequences. The label on the nucleotide(s) may be any signal
generating moiety, including, inter alia, radioisotopes, e.g.,
.sup.32 P or .sup.3 H, fluorescent molecules, e.g., fluorescein and
chromogenic molecules or enzymes, e.g., peroxidase, as described
earlier. Chromogenic agents are preferred for detection analysis,
e.g., by an enzyme linked chromogenic assay.
In a still preferred aspect, digoxinin-labelled nucleotides are
utilized. In such cases the PCR product, tagged with
digoxinin-labelled nucleotides is detectable when incubated with an
antidigoxinin antibody-alkaline phosphatase conjugate. The alkaline
phosphatase-based calorimetric detection utilizes nitroblue
tetrazolium, which, in the presence of
5-Bromo-4-chloro-3-indolyl-phosphate, yields a purpleblue
precipitate at the amplification site of the probe.
In one aspect of the present invention, the ligation and the PCR
amplification step of the in situ LD-PCR detection method can be
carried out simultaneously and at a higher temperature, by using a
thermostable ligase enzyme to circularize the amplification
probe.
In accordance with the present invention, further embodiments of in
situ LD-PCR may utilize amplification probes that are designed to
detect various genotypic variants of a pathogen e.g. HCV, that are
based on the known HCV sequences of these variants (Stuyver et al.,
1993, J.Gen. Vir. 74:1093-1102). For example, different
type-specific probes may be added together to the sample, and
detection of HCV sequences and amplification of the probe sequences
carried out by in situ LD-PCR as described above. Next, the
amplified probe sequences are assayed for the presence of
individual variant genotypes by in situ hybridization with type
specific internal probes that are labelled to facilitate
detection.
In certain aspects of the invention, the target nucleic acid
sequence may be directly detected using the various amplification
probes and/or amplification sequences described above, without
amplification of these sequences. In such aspects, the
amplification probes and/or amplification sequences may be labelled
so that they are detectable.
In embodiments of the present invention utilizing a ligation
dependent circularizable probe, the resulting circular molecule may
be conveniently amplified by the ramification-extension
amplification method (RAM), as depicted in FIG. 19. Amplification
of the circularized probe by RAM adds still further advantages to
the methods of the present invention by allowing up to a
million-fold amplification of the circularized probe under
isothermal conditions. RAM is illustrated in FIG. 19.
The single, full length, ligation dependent circularizable probe
useful for RAM contains regions at its 3' and 5' termini that are
hybridizable to adjacent but not contiguous regions of the target
molecule. The circularizable probe is designed to contain a 5'
region that is complementary to and hybridizable to a portion of
the target nucleic acid, and a 3' region that is complementary to
and hybridizable to a portion of the target nucleic acid adjacent
to the portion of the target that is complementary to the 5' region
of the probe. The 5' and 3' regions of the circularizable probe may
each be from about 20 to about 35 nucleotides in length. In a
preferred embodiment, the 5' and 3' regions of the circularizable
probe are about 25 nucleotides in length. The circularizable probe
further contains a region designated as the linker region. In a
preferred embodiment the linker region is from about 30 to about 60
nucleotides in length. The linker region is composed of a generic
sequence that is neither complementary nor hybridizable to the
target sequence.
The circularizable probe suitable for amplification by RAM is
utilized in the present method with one or more
capture-amplification probes, as described hereinabove. When the
circularizable probe hybridizes with the target nucleic acid, its
5' and 3' termini become juxtaposed. Ligation with a linking agent
results in the formation of a closed circular molecule.
Amplification of the closed circular molecule is effected by adding
a first extension primer (Ext-primer 1) to the reaction. Ext-primer
1 is complementary to and hybridizable to a portion of the linker
region of the circularizable probe, and is preferably from about 15
to about 30 nucleotides in length. Ext-primer 1 is extended by
adding sufficient concentrations of dNTPs and a DNA polymerase to
extend the primer around the closed circular molecule. After one
revolution of the circle, i.e., when the DNA polymerase reaches the
Ext-primer 1 binding site, the polymerase displaces the primer and
its extended sequence. The polymerase thus continuously "rolls
over" the closed circular probe to produce a long single strand
DNA, as shown in FIG. 19.
The polymerase useful for amplification of the circularized probe
by RAM may be any polymerase that lacks 3'.fwdarw.5' exonuclease
activity, that has strand displacement activity, and that is
capable of primer extension of at least about 1000 bases.
(Exo-)Klenow fragment of DNA polymerase. Thermococcus litoralis DNA
polymerase (Vent (exo-) DNA polymerase, New England Biolabs) and
phi29 polymerase (Blanco et al., 1994, Proc. Natl. Acad. Sci. USA
91:12198) are preferred polymerases. Thermus aquaticus (Taq) DNA
polymerase is also useful in accordance with the present invention.
Contrary to reports in the literature, it has been found in
accordance with the present invention that Taq DNA polymerase has
strand displacement activity.
Extension of Ext-primer 1 by the polymerase results in a long
single stranded DNA of repeating units having a sequence
complementary to the sequence of the circularizable probe. The
single stranded DNA may be up to 10 Kb, and for example may contain
from about 20 to about 100 units, with each unit equal in length to
the length of the circularizable probe, for example about 100
bases. As an alternative to RAM, detection may be performed at this
step if the target is abundant or the single stranded DNA is long.
For example, the long single stranded DNA may be detected at this
stage by visualizing the resulting product as a large molecule on a
polyacrylamide gel.
In the next step of amplification by RAM, a second extension primer
(Ext-primer 2) is added. Ext-primer 2 is preferably from about 15
to about 30 nucleotides in length. Ext-primer 2 is identical to a
portion of the linker region that does not overlap the portion of
the linked region to which Ext-primer 1 is complementary. Thus each
repeating unit of the long single stranded DNA contains a binding
site to which Ext-primer 2 hybridizes. Multiple copies of the
Ext-primer 2 thus bind to the long single stranded DNA, as depicted
in FIG. 19, and are extended by the DNA polymerase. The primer
extension products displace downstream primers with their
corresponding extension products to produce multiple displaced
single stranded DNA molecules, as shown in FIG. 19. The displaced
single strands contain binding sites for Ext-primer 1 and thus
serve as templates for further primer extension reactions to
produce the multiple ramification molecule shown in FIG. 19. The
reaction comes to an end when all DNA becomes double stranded.
The DNA amplified by RAM is then detected by methods known in the
art for detection of DNA. Because RAM results in exponential
amplification, the resulting large quantities of DNA can be
conveniently detected, for example by gel electrophoresis and
visualization for example with ethidium bromide. Because the RAM
extension products differ in size depending upon the number of
units extended from the closed circular DNA, the RAM products
appear as a smear or ladder when electrophoresed. In another
embodiment, the circularizable probe is designed to contain a
unique restriction site, and the RAM products are digested with the
corresponding restriction endonuclease to provide a large amount of
a single sized fragment of one unit length i.e., the length of the
circularizable probe. The fragment can be easily detected by gel
electrophoresis as a single band. Alternatively, a ligand such as
biotin or digoxigenin can be incorporated during primer extension
and the ligand-labeled single stranded product can be detected as
described hereinabove.
The RAM extension products can be detected by other methods known
in the art, including, for example, ELISA, as described hereinabove
for detection of PCR Products.
In other embodiments of the present invention, the RAM assay is
modified to increase amplification. In one embodiment, following
the addition of Ext-primer 2, the reaction temperature is
periodically raised to about 95.degree. C. The rise in temperature
results in denaturation of double stranded DNA, allowing additional
binding of Ext-primers 1 and 2 and production of additional
extension products. Thus, PCR can be effectively combined with RAM
to increase amplification, as depicted in FIG. 16.
In another embodiment, the Ext-2 primer (and thus the identical
portion of the linker region of the circularizable probe) is
designed to contain a promoter sequence for a DNA-dependent RNA
polymerase. RNA polymerases and corresponding promoter sequences
are known in the art, and disclosed for example by Milligan et al.
(1987) Nucleic Acid Res. 15:8783. In a preferred embodiment the RNA
polymerase is bacteriophage T3, T7, or SP6 RNA polymerase. Addition
of the Ext-primer 2 containing the promoter sequence, the
corresponding RNA polymerase and rNTPs, allows hybridization of
Ext-primer 2 to the growing single-stranded DNA to form a
functional promoter, and transcription of the downstream sequence
into multiple copies of RNA. This embodiment of the invention is
illustrated in FIG. 17. In this embodiment, both RAM and
transcription operate to produce significant amplification of the
probe. The RNA can be detected by methods known to one of ordinary
skill in the art, for example, polyacrylamide gel electrophoresis,
radioactive or nonradioactive labeling and detection methods
(Boehringer Mannheim), or the Sharp detection assay (Digene, Md.).
Detection of the RNA indicates the presence of the target nucleic
acid.
In another embodiment, Ext-primer 1 and the corresponding part of
the linker region of the circular probe are designed to have a
DNA-dependent RNA polymerase promoter sequence incorporated
therein. Thus when Ext-primer 1 binds the circularized probe, a
functional promoter is formed and the circularized probe acts as a
template for RNA transcription upon the addition of RNA polymerase
and rNTPs. The downstream primer and its RNA sequence are displaced
by the RNA polymerase, and a large RNA polymer can be made. The RNA
polymer may be detected as described hereinabove. Alternatively,
the circular probe can be cleaved into a single stranded DNA by
adding a restriction enzyme such as EcoRI. The restriction site is
incorporated into the 5' end of extension primer 1, as shown in
FIG. 20.
Reagents for use in practicing the present invention may be
provided individually or may be packaged in kit form. For example,
kits might be prepared comprising one or more first, e.g.,
capture/amplification-1 probes and one or more second, e.g.,
amplification-probe-2 probes, preferably also comprising packaged
combinations of appropriate generic primers. Kits may also be
prepared comprising one or more first, e.g.,
capture/amplification-1 probes and one or more second, full length,
ligation-independent probes, e.g., amplification-probe-2. Still
other kits may be prepared comprising one or more first, e.g.,
capture/amplification-1 probes and one or more second, full length,
ligation-dependent circularizable probes, e.g.,
amplification-probe-2. Such kits may preferably also comprise
packaged combinations of appropriate generic primers. Optionally,
other reagents required for ligation (e.g., DNA ligase) and,
possibly, amplification may be included. Additional reagents also
may be included for use in quantitative detection of the amplified
ligated amplification sequence, e.g., control templates such as an
oligodeoxyribonucleotide corresponding to nanovariant RNA. Further,
kits may include reagents for the in situ detection of target
nucleic acid sequences e.g., in tissue samples. The kits containing
circular probes may also include exonuclease for carryover
prevention.
The arrangement of the reagents within containers of the kit will
depend on the specific reagents involved. Each reagent can be
packaged in an individual container, but various combinations may
also be possible.
The present invention is illustrated with the following examples,
which are not intended to limit the scope of the invention.
EXAMPLE 1
DETECTION OF HIV-1 RNA IN A SAMPLE
Preparation of Oligonucleotide Probes
A pair of oligodeoxyribonucleotide probes, designated
Capture/Amp-probe-1 (HIV) and Amp-probe-2 (HIV), respectively for
detecting the gag region of HIV-1 RNA were prepared by automated
synthesis via an automated DNA synthesizer (Applied Biosystems,
Inc.) using known oligonucleotide synthetic techniques.
Capture/Amp-probe-1 (HIV) is an oligodeoxyribonucleotide comprising
59 nucleotides and a 3' biotin moiety, which is added by using a
3'-biotinylated nucleoside triphosphates as the last step in the
synthesis. The Capture/Amp-probe-1 (HIV) used in this Example has
the following nucleotide sequence (also listed below as SEQ ID NO.
1):
1 11 21 5'- CCATCTTCCT GCTAATTTTA AGACCTGGTA 31 41 51 ACAGGATTTC
CCCGGGAATT CAAGCTTGG -3'
The nucleotides at positions 24-59 comprise the generic 3' end of
the probe. Within this region are recognition sequences for SmaI
(CCCGGG), EcoRI (GAATTC) and HindIII (AAGCTT) at nucleotides 41-46,
46-51 and 52-57, respectively. The 5' portion of the sequence
comprising nucleotides 1-23 is complementary and hybridizes to a
portion of the gag region of HIV-1 RNA.
Amp-probe-2 (HIV) is a 92 nucleotide oligodeoxyribonucleotide which
has the following sequence (also listed below as SEQ ID NO. 2):
1 11 21 31 41 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT
TCGAGTAGAG 51 61 71 81 91 AGGTGAGAAA ACCCCGTTAT CTGTATGTAC
TGTTTTTACT GG -3'
The nucleotides at positions 71-92 comprise the 3' specific portion
of this probe, complementary and hybridizable to a portion of the
gag region of HIV-1 RNA immediately adjacent to the portion of the
gag region complementary to nucleotides 1-23 of Capture/Amp-probe-1
(HIV). Nucleotides 1-70 comprise the generic 5' portion of
Amp-probe-2 (HIV).
Ligation of the 5' end of Capture/Amp-probe-1 (HIV) to the 3' end
of Amp-probe-2 (HIV) using T.sub.4 DNA ligase creates the ligated
amplification sequence (HIV) having the following sequence (also
listed below as SEQ ID NO. 3):
1 11 21 31 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT 41 51 61
71 TCGAGTAGAG AGGTGAGAAA ACCCCGTTAT CTGTATGTAC 81 91 101 111
TGTTTTTACT GGCCATCTTC CTGCTAATTT TAAGACCTGG 121 131 141 151
TAACAGGATT TCCCCGGGAA TTCAAGCTTG G -3'
This ligated amplification sequence is 151 nucleotides long, which
provides an ideal sized template for PCR.
The generic nucleotide sequences of the ligated amplification
sequence (HIV) comprising nucleotides 116-135 (derived from
nucleotides 24-43 of Capture/Amp-probe-1 (HIV) and nucleotides 1-70
(derived from nucleotides 1-70 of Amp-probe-2 (HIV)) correspond in
sequence to nucleotides 1-90 of the (-) strand of the WSI
nanovariant RNA described by Schaffner et al. J. Molec. Biol.
117:877-907 (1977). WSI is one of a group of three closely related
6 S RNA species. WSE, WSII and WSIII, which arose in Q.beta.
replicase reactions without added template. Schaffner et al. termed
the three molecules, "nanovariants."
The 90 nucleotide long oligodeoxyribonucleotide corresponding to
nucleotides 1-90 of the WSI (-) strand has the following sequence
(also listed below as SEQ ID NO. 4):
1 11 21 31 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT 41
TCGAGTAGAG 51 61 71 81 AGGTGAGAAA ACCCCGTTAT CCTGGTAACA GGATTTCCCC
-3'
Two generic oligodeoxynucleotide primers were also synthesized for
use in PCR amplification of the ligated amplification sequence.
Primer-1, which has a length of 21 nucleotides, is complementary to
the 3' sequence of Capture/Amp-probe-1 (HIV) (nucleotides 38-58)
and has the sequence (also listed below as SEQ ID NO. 5):
1 11 5'- CAAGCTTGAA TTCCCGGGGA A -3'
Primer-2, which has a length of 20 nucleotides, corresponds in
sequence to the 5' sequence of Amp-probe-2 (HIV) (nucleotides 1-20)
and has the sequence (also listed below as SEQ ID NO. 6):
1 11 5'- GGGTTGACCC GGCTAGATCC -3'
Capture and Detection of HIV-1 RNA
Target HIV-1 RNA (100 .mu.l)is dissolved in an equal volume of
lysis buffer comprising 5M GnSCN, 100 mM EDTA, 200 mM Tris-HCl (pH
8.0). 0.5% NP-40 (Sigma Chemical Co., St. Louis, Mo.), and 0.5% BSA
in a 1.5 ml microfuge tube. Next, the 3'-biotinylated
Capture/Amp-probe-1 (HIV) (SEQ ID NO. 1) and Amp-probe-2 (HIV) (SEQ
ID NO. 2), together with streptavidin-coated paramagnetic beads
(obtained from Promega Corp.) were added to the lysed sample in the
lysis buffer. A complex comprising target RNA/Capture/Amp-probe-1
(HIV)/Amp-probe-2 (HIV)/paramagnetic beads was formed and retained
on the beads. A magnetic field generated by a magnet in a microfuge
tube holder rack (obtained from Promega Corp.) was applied to the
complex to retain it on the side of the reaction tube adjacent the
magnet to allow unbound material to be siphoned off. The complex
was then washed twice with a 1.5M GnSCN buffer to remove any
unbound proteins, nucleic acids, and probes that may be trapped
with the complex. The magnetic field technique facilitated the wash
steps. The GnSCN then was removed by washing the complex with 300
mM KCl buffer (300 mM KCl, 50 mM Tris-HCl, pH 7.5, 0.5% Non-IDEP-40
1 mM EDTA).
The two probes were then covalently joined using T.sub.4 DNA ligase
(Boehringer Manheim) into a functional ligated amplification
sequence (HIV) (SEQ ID NO. 3), which can serve as a template for
PCR amplification. The ligation reaction was carried out in the
presence of a 1X ligation buffer comprising a 1:10 dilution of
10.times.T.sub.4 DNA ligase ligation buffer (660mM Tris-HCl, 50 mM
MgCl.sub.2, 10 mM dithioeryritol, 10 mM ATP--pH 7.5 at 20.degree.
C.)obtained from Boehringer Manheim.
The paramagnetic beads containing bound ligated amplification
sequence (HIV) were washed with 1.times.T.sub.4 DNA ligase ligation
buffer and resuspended in 100 .mu.l of 1.times.T.sub.4 DNA ligase
ligation buffer, 20 .mu.l of bead suspension was removed for the
ligation reaction, 2 .mu.l T.sub.4 DNA ligase was added to the
reaction mixture, which was incubated at 37.degree. C. for 60
minutes.
For PCR amplification of the bound ligated amplification sequence
(HIV), 80 .mu.l of a PCR reaction mixture comprising Taq DNA
polymerase, the two generic PCR primers (SEQ ID NOS. 5 and 6), a
mixture of deoxynucleoside triphosphates and .sup.32 P -dCTP was
added to the ligation reaction. A two temperature PCR reaction was
carried out for 30 cycles in which hybrid formation and primer
extension was carried out at 65.degree. C. for 60 seconds and
denaturation was carried out at 92.degree. C. for 30 seconds.
After 30 cycles, 10 .mu.l of the reaction mixture was subjected to
electrophoresis in a 10% polyacrylamide gel and detected by
autoradiography (FIG. 3, Lane A). As a control, nanovariant DNA
(SEQ ID NO. 4) was also subjected to 30 cycles of two temperature
PCR, under the same conditions as for the ligated amplification
sequence (HIV), electrophoresed and autoradiographed (FIG. 3, Lane
B). As can be seen from FIG. 3, the amplified ligated amplification
sequence (HIV) migrated in a single band (151 nucleotides) at a
slower rate than the amplified nanovariant DNA (90 nucleotides).
The results also indicated that unligated firs t and second probes
were either not amplified or detected.
EXAMPLE 2
DIRECT DETECTION OF HIV-1 RNA IN A SAMPLE
The ability of the present method to directly detect the presence
of HIV-1 RNA in a sample was also determined. The probes used in
this Example are the same as in Example 1 (SEQ ID NOS. 1 and 2).
For direct detection, Amp-probe-2 (HIV) (SEQ ID NO. 2) was labeled
at its 5' end with .sup.32 P by the T.sub.4 phosphokinase reaction
using .sup.32 P-.gamma.-ATP. The various reaction mixtures were as
follows: 1. Streptavidin-coated paramagnetic beads, 3'-biotinylated
Capture/Amp-probe-1 (HIV) (SEQ ID NO. 1), Amp-probe-2 (HIV) (SEQ ID
NO. 2) 5' (.sup.32 P), HIV-1 RNA transcript. 2. Streptavidin-coated
paramagnetic beads, 3'-biotinylated Capture/Amp-probe-1 (HIV),
Amp-probe-2 (HIV) 5' (.sup.32 P). 3. Streptavidin-coated
paramagnetic beads, Amp-probe-2 (HIV) 5 (.sup.32 P), HIV-1 RNA
transcript.
Hybridizations, using each of the above three reaction mixtures,
were carried out in 20 .mu.l of a 1M GnSCN buffer comprising 1M
GnSCN, 0.5% NP-40 (Nonidet P-40, N-lauroylsarcosine, Sigma Chemical
Co., St. Louis, Mo.) 80 mM EDTA, 400 mM Tris HCl (pH 7.5) and 0.5%
bovine serum albumin.
The reaction mixtures were incubated at 37.degree. C. for 60
minutes. After incubation, the reaction mixtures were subjected to
a magnetic field as described in Example 1 and washed
(200.mu.l/wash) two times with 1M GnSCN buffer and three times with
a 300 mM KCl buffer comprising 300 mM KCL, 50 mM Tris-HCl (pH 7.5),
0.5% NP-40 and 1 mM EDTA. The amount of .sup.32 P-labeled
Amp-probe-2 (HIV) that was retained on the paramagnetic beads after
washing is reported in Table 1 as counts-per-minute (CPM). The
results indicate that, only in the presence of both target HIV RNA
and Capture/Amp-probe-1 (HIV), is a significant amount of
AMP-probe-2 retained on the beads and detected by counting in a
.beta.-scintillation counter.
TABLE 1 Capture of target HIV RNA with Capture/Amp-probe-1 (HIV)
CPM CPM Reaction (after 2 washes (after 3 washes Mixture with 1 M
GnSCN) with 0.3 M KCl) 1. 6254 5821 2. 3351 2121 3. 3123 2021
EXAMPLE 3
DETECTION OF MYCOBACTERIUM AVIUM-INTRACELLULAIRE (MAI) IN PATIENT
SAMPLES.
A recent paper (Boddinghaus et al., J. Clin. Microbiol. 28:1751,
1990) has reported successful identification of Mycobacteria
species and differentiation among the species by amplification of
16S ribosomal RNAs (rRNAs). The advantages of using bacterial 16S
rRNAs as targets for amplification and identification were provided
by Rogall et al., J. Gen. Microbiol., 136:1915, 1990 as follows: 1)
rRNA is an essential constituent of bacterial ribosomes; 2)
comparative analysis of rRNA sequences reveals some stretches of
highly conserved sequences and other stretches having a
considerable amount of variability; 3) rRNA is present in large
copy numbers, i.e. 10.sup.3 to 10.sup.4 molecules per cell, thus
facilitating the development of sensitive detection assays; 4) the
nucleotide sequences of 16S rRNA can be rapidly determined without
any cloning procedures and the sequence of most Mycobacterial 16S
rRNAs are known.
Three pairs of Capture/Amp-probe-1 and Amp-probe-2 probes are
prepared by automated oligonucleotide synthesis (as above), based
on the 16S rRNA sequences published by Boddinghaus et al., and
Rogall et al. The first pair of probes (MYC) is generic in that the
specific portions of the first and second probes are hybridizable
to 16S RNA of all Mycobacteria spp; this is used to detect the
presence of any mycobacteria in the specimen. The second pair of
probes (MAV) is specific for the 16S rRNA of M. avium, and the
third pair of probes (MIN) is specific for the 16S rRNA of M.
intracellulaire. The extremely specific ligation reaction of the
present method allows the differentiation of these two species at a
single nucleotide level.
A. The probes that may be used for generic detection of all
Mycobacter spp. comprise a first and second probe as in Example 1.
The first probe is a 3' biotinylated Capture/Amp-probe-1 (MYC), an
oligodeoxyribonucleotide of 54 nucleotides in length with the
following sequence (also listed below as SEQ ID NO. 7):
1 11 21 31 5'- CAGGCTTATC CCGAAGTGCC TGGTAACAGG ATTTCCCCGG 41 51
GAATTCAAGC TTGG -3'
Nucleotides 1-18, at the 5' end of the probe are complementary to a
common portion of Mycobacterial 16S rRNA, i.e., a 16S rRNA sequence
which is present in all Mycobacteria spp. The 3' portions of the
probe, comprising nucleotides 19-54 is identical in sequence to the
36 nucleotides comprising the generic portion of
Capture/Amp-probe-1 (HIV) of Example 1.
The second probe is AMP-probe-2 (MYC), an oligodeoxyribonucleotide
of 91 nucleotides in length, with the following sequence (also
listed below as SEQ ID NO. 8):
1 11 21 31 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT 41 51 61
71 TCGAGTAGAG AGGTGAGAAA ACCCCGTTAT CCGGTATTAG 81 91 ACCCAGTTTC C
-3'
Nucleotides 71-91 at the 3' end of the probe are complementary to a
common portion of 16S rRNA adjacent the region complementary to
nucleotides 1-18 or Capture/Amp-probe-1 (MYC) disclosed above,
common to all Mycobacteria spp. Nucleotides 1-70 at the 5' end of
the probe comprise the same generic sequence set forth for
Amp-probe-2 (HIV) in Example 1.
End to end ligation of the two probes, as in Example 1, provides
ligated amplification sequence (MYC), 145 nucleotides in length,
for detection of all Mycobacteria spp., having the following
sequence (also listed below as SEQ ID NO. 9):
1 11 21 31 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT 41 51 61
71 TCGAGTAGAG AGGTGAGAAA ACCCCGTTAT CCGGTATTAG 81 91 101 111
ACCCAGTTTC CCAGGCTTAT CCCGAAGTGC CTGGTAACAG 121 131 141 GATTTCCCCG
GGAATTCAAG CTTGG -3'
B. The pair of probes for specific detection of M. avium are as
follows: The first probe is a 3' biotinylated-Capture/Amp-probe-1
(MAV), an oligodeoxyribonucleotide of 56 nucleotides in length with
the following sequence (also listed below as SEQ ID NO. 10:
1 11 21 31 5'- GAAGACATGC ATCCCGTGGT CCTGGTAACA GGATTTCCCC 41 51
GGGAATTCAA GCTTGG -3'
Nucleotides 1-20 at the 5'-end are complementary to a portion of
16S rRNA specific for M. avium. Nucleotides 21-56 comprise the same
generic sequence, as above.
The second probe is Amp-probe-2 (MAV), an oligodeoxyribonucleotide
of 90 nucleotides in length, with the following sequence (also
listed below as SEQ ID NO. 11):
1 11 21 31 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT 41 51 61
71 TCGAGTAGAG AGGTGAGAAA ACCCCGTTAT CGCTAAAGCG 81 CTTTCCACCA
-3'
Nucleotides 71-90 at the 3' end of the probe comprise the specific
nucleotide sequence complementary to a region of 16S rRNA specific
for M. avium, adjacent the specific sequences recognized by
Capture/Amp-probe-1 (MAV). Nucleotides 1-70 comprise the same
generic sequence as above.
End to end ligation of the two probes provides a 146 nucleotide
long ligated amplification sequence (MAV) for detection of M. avium
having the following sequence (also listed below as SEQ ID NO.
12):
1 11 21 31 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT 41 51 61
71 TCGAGTAGAG AGGTGAGAAA ACCCCGTTAT CGCTAAAGCG 81 91 101 111
CTTTCCACCA GAAGACATGC ATCCCGTGGT CCTGGTAACA 121 131 141 GGATTTCCCC
GGGAATTCAA GCTTGG -3'
C. The pair of probes for specific detection of M. intracellulaire
are as follows: The first probe is a 3'-biotinylated
Capture/Amp-probe-1 (MIN), an oligonucleotide of 56 nucleotides in
length with the following sequence (also listed below as SEQ ID NO.
13):
1 11 21 31 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT 41 51
GGGAATTCAA GCTTGG -3'
Nucleotides 1-20 at the 5' end are complementary to a portion of
16S rRNA specific for M. intracellulaire. Nucleotides 21-56
comprise the same generic sequence as above.
The second probe is Amp-probe-2 (MIN), an oligodeoxyribonucleotide
or 90 nucleotides in length, with the following sequence (also
listed below as SEQ ID NO. 14):
1 11 21 31 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT 41 51 61
71 TCGAGTAGAG AGGTGAGAAA ACCCCGTTAT CGCTAAAGCG 81 CTTTCCACCT
-3'
Nucleotides 71-90 at the 3' end of the probe comprise the specific
nucleotide sequence complementary to a region of M. intracellulaire
16S rRNA adjacent the specific sequence recognized by
Capture/Amp-probe-1 (MIN).
End to end ligation of the two probes provides a 146 nucleotide
long ligated amplification sequence (MIN) for detection of M.
intracellulaire, having the following sequence (also listed below
as SEQ ID NO. 15):
1 11 21 31 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT 41 51 61
71 TCGAGTAGAG AGGTGAGAAA ACCCCGTTAT CGCTAAAGCG 81 91 101 111
CTTTCCACCT AAAGACATGC ATCCCGTGGT CCTGGTAACA 121 131 141 GGATTTCCCC
GGGAATTCAA GCTTGG -3'
D. In order to detect the presence of the above Mycobacteria spp.,
patients' blood specimens are collected in Pediatric Isolator Tubes
(Wampole Laboratories, N.J.). The Isolator's lysis centrifugation
technique enables separation of blood components, followed by lysis
of leukocytes to improve recovery of intracellular organisms
(Shanson et al., J. Clin. Pathol. 41:687, 1988). After lysis, about
120 .mu.l of concentrated material is dissolved in an equal volume
of the 5M GnSCN buffer of Example 1. The mixture is boiled for 30
minutes, which because of the nature of mycobacterial cell walls,
is required for lysis of Mycobacteria spp. The subsequent
procedures (i.e., capture, ligation, PCR and detection) are the
same as those employed in Example 1.
Before the PCR amplification, a direct detection is made by
measuring radioactivity representing .sup.32 P-5'-AMP-probe-2
captured on the magnetic beads. After the unbound
radioactively-labeled Amp-probe-2 is removed by extensive washing,
the target 16S rRNA molecules that are present in concentrations of
more than 10.sup.6 /reaction is detectable. Target 16S rRNA that
cannot be detected directly is subjected to PCR amplification of
the ligated amplification sequences as per Example 1. The primers
for use in amplification are the same two generic primers of
Example 1 (SEQ ID NOS. 5 and 6).
EXAMPLE 4
DETECTION OF HCV RNA IN A SAMPLE
Hepatitis C virus (HCV), an RNA virus, is a causative agent of post
transfusion hepatitis. HCV has been found to be distantly related
to a flavivirus and pestivirus and thus its genome has a 5' and a
3' untranslated region (UTR) and encodes a single large open
reading frame (Lee et al., J. Clin. Microbiol. 30:1602-1604, 1992).
The present method is useful for detecting the presence of HCV in a
sample.
A pair of oligodeoxynucleotide probes, designated
Capture/Amp-probe-1 (HCV) and Amp-probe-2 (HCV), respectively, for
targeting the 5' UTR of HCV RNA are prepared as in Example 1.
Capture/Amp-probe-1 (HCV), which is biotinylated at the 3' end, is
a 55 nucleotide long oligodeoxyribonucleotide having the following
nucleotide sequence (also listed below as SEQ ID NO. 16):
1 11 21 31 5'- GCAGACCACT ATGGCTCTCC CTGGTAACAG GATTTCCCCG 41 51
GGAATTCAAG CTTGG -3'
Nucleotides 1-19 at the 5' end of Capture/Amp-probe-1 (HCV)
comprise a specific sequence complementary to a portion of the 5'
UTR of the HCV genome. Nucleotides 20-55 at the 3' end of the probe
comprise the same 36 nucleotide generic sequence as in
Capture/Amp-probe-1 (HIV) of Example 1.
Amp-probe-2 (HCV) is a 90 nucleotide long oligodeoxyribonucleotide
having the following nucleotide sequence (also listed below as SEQ
ID NO. 17):
1 11 21 31 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT 41 51 61
71 TCGAGTAGAG AGGTGAGAAA ACCCCGTTAT CCGGTGTACT 81 CACCGGTTCC
-3'
Nucleotides 71-90 comprise the 3' specific portion of the probe,
complementary and hybridizable to a portion of the HCV 5' UTR
immediately adjacent to the portion of the HCV genome hybridizable
to nucleotides 1-19 of Capture/Amp-probe-2 (HCV). Nucleotides 1-70
comprise the same generic sequence as in Amp-probe-2 (HIV) of
Example 1.
End to end ligation of the two probes as in Example 1 provides a
145 nucleotide long ligated amplification sequence (HCV) for
detection of HCV in a sample, having the sequence (also listed
below as SEQ ID NO. 18):
1 11 21 31 5'- GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT 41 51 61
71 TCGAGTAGAG AGGTGAGAAA ACCCCGTTAT CCGGTGTACT 81 91 101 111
CACCGGTTCC GCAGACCACT ATGGCTCTCC CTGGTAACAG 121 131 141 GATTTCCCCG
GGAATTCAAG CTTGG -3'
The ligated amplification sequence (HCV) is amplified using a two
temperature PCR reaction as in Example 1. The PCR primers used for
amplification are the same two generic primers (SEQ ID NOS. 5 and
6) of Example 1.
EXAMPLE 5
USE OF MULTIPLE CAPTURE AND AMPLIFICATION PROBES TO DETECT HCV RNA
IN A SAMPLE
A pair of amplication probes and two capture/amplification probes
were used to assay for and detect HCV RNA in a sample, thereby
increasing the capture efficiency of the assay.
The capture/amplification probes Capture/Amp-probe-1 (HCV A) (all
oligomers described in this Example are designated "(HCV A)" to
distinguish from the probes "(HCV)" of Example 4) having a SEQ ID
NO. 22 and Capture/Amp-probe-1A (HCV A) having SEQ ID NO. 23 are
designed and synthesized such that their 5' termini are
biotinylated and the 3' region of the probes comprises sequences
complementary to and hybridizable with sequences in the 5'UTR of
HCV RNA (FIG. 4). The generic nucleotide sequence at the 5' region
of the probes that are not hybridizable to the target nucleic acid
sequence are designed and synthesized to have random sequences and
a GC content of, at least, 60%, and such that they exhibit minimal
secondary structure e.g. hairpin or foldback structures.
Capture/Amp-probe-1 (HCV A) which is biotinylated at the 5'
terminus, is a 45 nucleotide DNA oligomer, such that nucleotides 5
to 45 in the 3' region, are complementary to and hybridizable with
sequences in the 5'UTR of the target HCV RNA, and that the oligomer
has the following nucleotide sequence (also listed below as SEQ ID
NO. 22):
5'- AAGAGCGTGA AGACAGTAGT TCCTCACAGG GGAGTGATTC ATGGT -3'
Capture/Amp-probe-1A (HCV A) which is also biotinylated at the 5'
terminus, is also a 45 nucleotide DNA oligomer, such that
nucleotides 5 to 45 in the 3' region are complementary to and
hybridizable with sequences in the 5'UTR of HCV RNA that are
immediately adjacent to the region of the 5'UTR of the HCV RNA
hybridizable with Capture/Amp-probe-1 (HCV A) and such that the
oligomer has the following nucleotide sequence (also listed below
as SEQ ID NO. 23):
5'- AAGACCCAAC ACTACTCGGC TAGCAGTCTT GCGGGGGCAC GCCCA -3'
The two amplification probes Amp-probe-2 (HCV A) and Amp-probe-2A
(HCV A) each contain a nucleotide sequence complementary to and
hybridizable with the conserved 5'UTR of HCV RNA.
Amp-probe-2 (HCV A) is a 51 nucleotide oligomer such that
nucleotides 1 to 30 in the 5' region are complementary to and
hybridizable with sequences in the 5'UTR of HCV RNA, and that the
nucleotides 34 to 51 at the 3' terminus bind to and hybridize with
PCR primer-3 and such that the oligomer has the following
nucleotide sequence (also listed below as SEQ ID NO. 24):
5'- ACTCACCGGT TCCGCAGACC ACTATGGCTC GTTGTCTGTG TATCTGCTAA C
-3'
Amp-probe-2A (HCV A) is a 69 nucleotide oligomer such that
nucleotides 40 to 69 in the 3' region are complementary to and
hybridizable with sequences in the 5'UTR of HCV RNA genome
immediately adjacent to the portion of the HVC RNA genome
hybridizable to nucleotides 1-30 of Amp-probe-2 (HCV A) and such
that the nucleotides 1 to 18 at the 5' terminus bind to and
hybridize with PCR primer-4 and such that nucleotides 19 to 36 at
the 5' terminus bind to and hybridize with PCR primer-5, and such
that the oligomer has the following nucleotide sequence (also
listed below as SEQ ID NO. 25):
5'- CAAGAGCAAC TACACGAATT CTCGATTAGG TTACTGCAGA GGACCCGGTC
GTCCTGGCAA TTCCGGTGT -3'
End to end ligation of the two probes provides a 120 nucleotide
ligated product, the ligation-amplification sequence (HCV A) that
serves as a detectable sequence for HCV as well as a template for
amplification reactions, and has the sequence (also listed below as
SEQ ID NO. 26):
5'- CAAGAGCAAC TACACGAATT CTCGATTAGG TTACTGCAGA GGACCCGGTC
GTCCTGGCAA TTCCGGTGTA CTCACCGGTT CCGCAGACCA CTATGGCTCG TTGTCTGTGT
ATCTGCTAAC -3'
Primer-3, used for the first series of PCR amplification of the
ligated amplification sequence, SEQ ID NO. 26 (HCV A), and which
has a length of 18 nucleotides, is complementary to sequence
comprising nucleotides 34 to 51 at the 3' terminus of Amp-probe-2
(HCV A), and is, therefore, also complementary to the sequence
comprising nucleotides 103 to 120 of the ligated amplification
sequence, SEQ ID NO. 26 (HCV A), and has the sequence (also listed
below as SEQ ID NO. 27):
5'- GTTAGCAGAT ACACAGAC -3'
Primer-4, used for the first series of PCR amplification of the
ligated amplification sequence (HCV A), SEQ ID NO. 26, and which
has a length of 18 nucleotides, is complementary to the sequence
comprising nucleotides 1-18 at the 5' terminus of the Amp-probe-2A
(HCV A), and is , therefore, also complementary to the sequence
comprising nucleotides 1 to 18 of the ligated amplification
sequence, SEQ ID NO. 26 (HCV A), and has the sequence (also listed
below as SEQ ID NO. 28):
5'- CAAGAGCAAC TACACGAA -3'
Primer-5, a DNA oligomer of 18 nucleotides is used for the second
series of PCR amplification of the ligated amplification sequence
(HCV A), SEQ ID NO. 26, such that the primer is complementary to
the sequence comprising nucleotides 19-36 of the Amp-probe-2A (HCV
A), and is, therefore, also hybridizable to the sequence comprising
nucleotides 19-36 of the ligated amplification sequence SEQ ID NO.
26 (HCV A), and has the sequence (also listed below as SEQ ID NO.
29):
5'- TTCTCGATTA GGTTACTG -3'
The assay utilizing the above probes and primers was used to detect
HCV RNA in 24 human serum samples that were stored at -70.degree.
C. until use. For the assay, 180 .mu.l serum sample was added to
concentrated lysis buffer (prepared by condensing 250 .mu.l of the
lysis solution containing 5M GnSCN, 0.5% bovine serum albumin, 80
mM EDTA, 400 mM Tris HCl (pH 7.5), and 0.5% Nonidet P-40 is that
the mixture of serum and lysis buffer would have a final
concentration of 5M GnSCN) mixed well and incubated for 1 hour at
37.degree. C. to release the target RNA from HCV particles. 80
.mu.l of the lysis mixture was then transferred to 120 .mu.l of
hybridization buffer [0.5% bovine serum albumin, 80 mM EDTA, 400 mM
Tris-Hcl (pH 7.5), 0.5 % Nonidet-P40] with 10.sup.10 molecules each
of amplification probes. Amp-probe-2 (HCV A) and Amp-probe-2A (HCV
A) oligomers, and 10.sup.11 molecules each of capture/amplification
probes. Capture/Amp-probe-1 (HCV A) and Capture/Amp-probe-1A (HCV
A). The addition of the hybridization buffer reduced the
concentration of the guanidium isothiocyanate (GnSCN) from 5M to 2M
to allow the hybridization to occur. The mixture was incubated at
37.degree. C. for 1 hour to let the various probes hybridize with
the target RNA, where-upon 30 .mu.l of streptavidin-coated
paramagnetic beads (Promega) were added to the hybridization
mixture before incubation at 37.degree. C. for 20 minutes to allow
ligand binding. Next, the beads were washed with 150 .mu.l of 2M
GnSCN to eliminate any free probes, proteins, extraneous nucleic
acids and potential PCR inhibitors from the hybridization mixture;
this was followed by the removal of the GnSCN by washing twice with
150 .mu.l ligase buffer [66 mM Tris-Hcl (pH 7.5) 1 mM DTT, 1 mM
ATP, 0.5% Nonidet P-40 and 1 mM MnCl.sub.2 ]. At each wash-step,
the magnetic separation of the bound complex from the supernatant
was effected by the magnetic field technique described in Example
1.
The amplification probes, Amp-probe-2 (HCV A) and Amp-probe-2A (HCV
A), bound to target RNA were then covalently joined to create the
ligated amplification sequence (HCV A) that was utilized as a
template for PCR amplification. The hybrid complex was resuspended
in 20 .mu.l ligase buffer with 5 units of T.sub.4 DNA ligase
(Boehringer) and incubated for 1 hour at 37.degree. C. for the
ligation reaction. For the subsequent PCR reaction referred to
hereafter as the "first PCR reaction", 10 .mu.l of the ligated
mixture, including the beads, was added to 20 .mu.l of PCR mixture
[0.06 .mu.M each of Primer-3 and Primer-4, 1.5 Units Taq DNA
Polymerase, 0.2 mM each of dATP, dCTP, dGTP, and dTTP, 1.5 mM
MgCl.sub.2. 10 mM Tris-HCl (pH 8.3) 5mM KCl] and the mixture
incubated at 95.degree. C. for 30 seconds, 55.degree. C. for 30
seconds and 72.degree. C. for 1 minute, for 35 cycles. After the
first PCR reaction, 5 .mu.l of the product was transferred to a
second PCR mixture [same components as the first PCR mixture except
that Primer-4 was substituted with Primer-5] for "the second PCR
reaction" (a semi-nested PCR approach to increase the sensitivity
of the assay) carried out under the same conditions as the first
PCR reaction. 10 .mu.l of the products of the second reaction were
electrophoresed on a 6% polyacrylamide gel, stained with ethidium
bromide and visualized under ultraviolet light.
To establish the sensitivity and the specificity of the method,
10-fold serial dilutions of synthetic HCV RNA in HCV-negative serum
were assayed according to the protocol described above, so that the
concentration of HCV RNA ranged from 10 to 10.sup.7
molecules/reaction. After ligation and amplification, the PCR
products were separated by polyacrylamide gel electrophoresis,
stained with ethidium bromide and visualized under ultra violet
light. The results, shown in FIG. 8, clearly indicate the
specificity of the method. In the absence of HCV RNA there is no
signal, indicating that probes must capture the target RNA in order
to generate a PCR product. As few as 100 molecules of HCV
RNA/sample were detectable with the semi-nested PCR method (FIG.
8), indicating that the sensitivity of the method is at least
comparable to that of conventional RT-PCR (Clementi et al., 1993,
PCR 2: 191-196).
Further, relative amounts of the PCr product represented by the
intensity of the bands as visualized in FIG. 8, were proportional
to the quantity of the target RNA (HCV RNA transcripts). Therefore,
the assay is quantitative over, at least, a range of 10.sup.2 to
10.sup.5 target molecules.
To determine the increased capture efficiency afforded by two
capture probes. .sup.32 P-labelled target HCV RNA was assayed for
capture and retention on paramagnetic beads using
Capture/Amp-probe-1 (HCV A) or Capture/Amp-probe-1A (HCV A) or
both. The capture was estimated by the amount of radioactivity
retained on the paramagnetic beads after extensive washes with
2M-GnSCN buffer and the ligase buffer. Results showed that 25.7% of
labelled HCV RNA was retained on the beads when captured by
Capture/Amp-probe-1 (HCV A) alone, 35.8% retained with
Capture/Amp-probe-1A (HCV A) alone and 41.5% of the target RNA was
retained when both the capture probes were used. Therefore the
double-capture method was more efficient than the use of a single
capture probe.
EXAMPLE 6
USE OF MULTIPLE CAPTURE AND AMPLIFICATION PROBES TO DETECT HIV-1
RNA IN A SAMPLE
An alternative approach to that set forth in Example 1 uses a
capture/amplification probe and a pair of amplication probes to
detect the presence of HIV-1 RNA. Capture/Amp-probe-1 (HIV), SEQ ID
NO. 1 and a pair of amplification probes Amp-probe-2 (HIV A) (all
oligomers described in this Example are designated "HIV A)" to
distinguish from the probes "(HIV)" of Example 1) (SEQ ID NO. 19)
and Amp-probe-2A (HIV A), (SEQ ID NO. 20), are utilized such that
the generic nucleotide sequences of the ligated amplification
sequence (HIV A) (SEQ ID NO. 21) comprising nucleotides 1-26
derived from nucleotides 1-26 of Amp-probe-2 (HIV A) and
nucleotides 86-112 derived from nucleotides 40-65 of Amp-probe-2A
(HIV A) are designed and synthesized to have random sequences and a
GC content of, at least, 60%, and such that they exhibit minimal
secondary structure e.g. hairpin or foldback structures.
Amplification probe Amp-probe-2 (HIV A) is a 47 nucleotide DNA
oligomer such that nucleotides 27 to 47 in the 3' region, are
complementary to and hybridizable with sequences in the gag region
of the target HIV-1 RNA, and that the oligomer has the following
nucleotide sequence (also listed below as SEQ ID NO. 19):
5'- GGTGAAATTG CTGCCATTGT CTGTATGTTG TCTGTGTATC TGCTAAC -3'
Amplification probe Amp-probe-2A (HIV A) is a 65 nucleotide DNA
oligomer such that nucleotides 1 to 39 in the 5' region, are
complementary to and hybridizable with sequences in the gag region
of the target HIV-1 RNA, immediately adjacent to the portion of the
HIV-1 RNA genome hybridizable to nucleotides 27-47 of the
Amp-probe-2 (HIV A) and that the oligomer has the following
nucleotide sequence (also listed below as SEQ ID NO. 20):
5'- CAAGAGCAAC TACACGAATT CTCGATTAGG TTACTGCAGC AACAGGCGGC
CTTAACTGTA GTACT -3'
End to end ligation of the two amplification probes provides a 112
nucleotide ligated amplification sequence (HIV A) such that the
sequence serves as a detectable sequence for HIV-1 RNA as well as a
template for amplification reactions, and has the following
sequence (also known as SEQ ID NO. 21)
5'- GGTGAAATTG CTGCCATTGT CTGTATGTTG TCTGTGTATC TGCTAACCAA
GAGCAACTAC ACGAATTCTC GATTAGGTTA CTGCAGCAAC AGGCGGCCTT AACTGTAGTA
CT -3'
Further, the capture, detection and optional amplification of the
captured ligation product in order to assay for HIV RNA is carried
out as described in Example 5. The PCR primers used for
amplification are the same primers -3, 4 and 5 (SEQ ID NOS. 27, 28
and 29) of Example 5.
EXAMPLE 7
USE OF SEPARATE CAPTURE/AMPLIFICATION PROBES AND A LIGATION
INDEPENDENT, SINGLE AMPLIFICATION PROBE TO DETECT HCV RNA IN A
SAMPLE
The assay employs a single ligation independent amplification probe
and two capture/amplification probes to detect HCV RNA in a
sample.
The capture/amplification probes Capture/Amp-probe-1 (HCV A) and
Capture/Amp-probe-1A (HCV A) used in this method are the same as
described in Example 5.
The amplification probe, Amp-probe-2 (HCV B) (all oligomers
described in this Example are designated "(HCV B)" to distinguish
from the probes "(HCV)" of Example 4), SEQ ID NO. 30, is a 100
nucleotide DNA molecule such that the sequence represented by
nucleotides 39 to 79 in the central region of the oligomer is
complementary to and hybridizable to a region in the 5' UTR of the
HCV RNA (FIG. 6), and that the sequences spanning nucleotides 1-38
in the 5' terminus and by nucleotides 80-100 in the 3' terminus are
designed and synthesized such that they have random sequences and a
GC content of, at least, 60% , and such that they exhibit minimal
secondary structure e.g. hairpin or foldback structures.
Amp-probe-2 (HCV B), also referred to as amplification sequence,
has the following sequence (also listed below as SEQ ID NO.
30):
5'- CAAGAGCAAC TACACGAATT CTCGATTAGG TTACTGCAGC GTCCTGGCAA
TTCCGGTGTA CTCACCGGTT CCGCAGACCG TTGTCTGTGT ATCTGCTAAC -3'
The capture, detection and the optional amplification of the probe
sequences was carried out as described in Example 5, except that
primers -3 and -4, only, were utilized in a single PCR
amplification step, the second PCR step was omitted, and that the
ligation step was omitted.
EXAMPLE 8
USE OF SEPARATE CAPTURE/AMPLIFICATION PROBES AND A SINGLE,
AMPLIFIABLE, LIGATION DEPENDENT PROBE TO DETECT HCV RNA IN A
SAMPLE
The method in this Example employs the two capture/amplification
probes Capture/Amp-probe-1 (HCV A) and Capture/Amp-probe-1A (HCV A)
described in Example 5 and a single amplification probe,
Amp-probe-2 (HCV C) (all oligomers described in this Example are
designated "(HCV C)" to distinguish from the probes "(HCV)" of
Example 4) that hybridizes to the target nucleic acid and
circularizes upon ligation of its free termini as shown in FIG.
7.
Amp-probe-2 (HCV C)is a 108 nucleotide amplification probe, also
referred to as an amplification sequence, such that nucleotides
1-26 in the 5' terminus of the oligomer are complementary to and
hybridizable to a sequence in the 5'UTR of the target HCV RNA
(indicated by (a) in FIG. 7) and such that nucleotides 83-108 at
the 3' terminus of the oligomer are complementary to and
hybridizable to a sequence in the 5'UTR of the target HCV RNA
(indicated by (b) in FIG. 7). Moreover, when the probe hybridizes
with the target HCV RNA, the 3' and 5' termini of the probe are
placed immediately adjacent to each other (FIG. 7), resulting in
the formation of a closed circular molecule upon ligation with a
linking agent, such as DNA ligase. The sequence of Amp-probe-2 (HCV
C) is given as follows (also listed as SEQ ID NO.31):
5'- CCTTTCGCGA CCCAACACTA CTCGGCTGTC TGTGTATCTG CTAACCAAGA
GCAACTACAC GAATTCTCGA TTAGGTTACT GCGCACCCTA TCAGGCAGTA CCACAAGG
-3'
Primer-3 (SEQ ID NO. 27), used for the first series of PCR
amplification of the ligated and circularized Amp-probe-2 (HCV C),
is an 18 nucleotide long oligomer that is complementary to the
sequence comprising nucleotides 27 to 45 of Amp-probe-2 (HCV
C).
Primer-4 (SEQ ID NO. 28), also used for the first series of PCR
amplification of the ligated and circularized Amp-probe-2, is a 18
nucleotide long oligomer that is complementary to the sequence
comprising nucleotides 46 to 63 of Amp-probe-2 (HCV C).
The hybridization of the two capture/amplification probes and the
amplification probe to target HCV RNA, circularization of the
amplification probe upon ligation of its termini and amplification
of the probe sequences was carried out as described in Example 5,
except that primers -3 and -4, only, were utilized in a single PCR
amplification step, the second PCR step was omitted, and that
Amp-probe-2 (HCV C) (SEQ ID NO. 31) was substituted for the pair of
amplification probes, Amp-probe-2 (HCV A) (SEQ ID NO. 24) and
Amp-probe-2A (HCV A) (SEQ ID NO. 25) utilized in Example 5.
To establish the sensitivity and the specificity of the method,
10-fold serial dilutions of synthetic HCV RNA in HCV-negative serum
were assayed according to the method to provide standard
concentrations of HCV RNA ranging from 10.sup.3 to 10.sup.7
molecules/sample. After ligation and amplification, the PCR
products were separated by polyacrylamide gel electrophoresis,
stained with ethidium bromide and visualized under ultra-violet
light.
The results, (FIG. 9, (-): control, no sample), indicate the
specificity of the method. The assay is highly specific; in the
absence of target HCV RNA there is no visible signal, indicating
that probes must capture the target RNA in order to generate a PCR
product. As seen in FIG. 9, as few as 10.sup.4 molecules of HCV
RNA/sample were clearly detectable.
Further, relative amounts of the PCR product, represented by the
intensity of the bands (FIG. 9), were proportional to the quantity
of the target RNA (HCV RNA transcripts). Therefore, the assay is
significantly quantitative at least over a range of 10.sup.4 to
10.sup.7 target molecules.
EXAMPLE 9
DETECTION OF HCV TARGET SEQUENCES IN TISSUE SAMPLE USING LD-PCR
ASSAY
This example provides a comparison of the ligation-dependent PCR
(LD-PCR) of the present invention with reverse transcriptase PCR
(RT-PCR) for the detection of HCV sequences in formalin fixed,
paraffin embedded (FFPE) liver samples. Twenty-one archival liver
specimens of hepatocellular carcinoma (HCCs) from patients who
underwent liver resection or orthotopic liver transplantation
between January, 1992 to March, 1995 at the Mount Sinai Medical
Center, New York, N.Y. were selected for this study. Thirteen of
these patients were anti-HCV positive and eight were negative as
determined by a second generation enzyme-linked immunoassay (EIA
II) (Abbott Diagnostic, Chicago, Ill.). An explanted liver tissue
from an anti-HCV negative patient with cirrhosis secondary to
biliary atresia was used as control. After surgery, the liver
specimens were stored at 4.degree. C. and sectioned within twelve
hours. The specimens were fixed in 10% buffered formalin for eight
to twelve hours and routinely embedded in paraffin. The FFPE
specimens were stored at room temperature for a period of three
months up to three years. In addition, snap frozen liver tissues
from thirteen of the twenty-two patients, stored at -70.degree. C.,
were used to resolve discordance between LD-PCR and RT-PCR
results.
FFPE specimens (approximately 2-4 cm.sup.2) were sectioned on a
microtome with a disposable blade to 10 .mu.m in thickness, and
each section was placed in a 1.5 -ml microcentrifuge tube. To avoid
cross contamination, the blades were changed and the holder was
cleaned with 10% Chlorox solution between each sample. The sections
were deparaffinized by incubating at 60.degree. C. for 10 minutes
in the presence of 1 ml of xylene (Sigma). The xylene was removed
by two washes with absolute ethanol. The specimens were then dried
by vacuum centrifugation or by placing on a hot block at 65.degree.
C. for 30 min.
For LD-PCR, the deparaffinized tissues were lysed by incubating at
100.degree. C. for 30 min in 250 .mu.l of lysis buffer containing
5M guanidinium thiocyanate (GnSCN) (Fluka), 0.5% bovine serum
albumin (Sigma), 80 mM EDTA, 400 mM Tris HCl (pH 7.5), and 0.5%
sodium-N-lauroylsarcosine (Sigma) followed by incubating at
65.degree. C. for 30 min. The lysed specimens were stored at
31.degree. C. until use. The HCV serologic status of all specimens
was blinded to laboratory personnel to avoid bias.
For RT-PCR, the deparaffinized tissues were lysed by incubating at
60.degree. C. for 5 hr in 200 .mu.l of lysis buffer containing 10
mM Tris-HCl (pH 8.0), 0.1 mM EDTA (ph 8.0), 2% sodium dodecyl
sulfate and 500 .mu.g/ml proteinase K. RNA was purified by phenol
and chloroform extractions followed by precipitation with an equal
volume of isopropanol in the presence of 0.1 volume of 3M sodium
acetate. The RNA pellet was washed once in 70% ethanol, dried and
resuspended in 30 .mu.l of sterile diethylpyrocarbonate-treated
water. RNA was also extracted from sections (10 nm thickness) of
frozen liver tissue obtained from the corresponding patients using
the single step RNA extraction method described by Chomczynski et
al. (1987) Anal. Biochem. 162: 156.
LD-PCR was performed as follows. Briefly, 80 .mu.l of lysis mixture
were added to 120 .mu.l of hybridization buffer [0.5% bovine serum
albumin, 80 mM EDTA, 400 Mm Tris-HCl (pH 7.5), and 0.5%
sodium-N-lauroylsarcosine], which contained 10.sup.10 molecules of
phosphorylated Amp-probe-2, 10.sup.10 molecules of Amp-probe 2A and
10.sup.11 molecules of capture Amp-probe 1 and capture Amp probe
1A. (Probes are as described in Example 5). Addition of the
hybridization buffer reduced the GnSCN concentration from 5M to 2M
to allow hybridization to occur. This mixture was incubated for one
hour to allow the formation of hybrids, consisting of two DNA
capture probes and two DNA hemiprobes bound to their HCV RNA
target. Thirty .mu.l of streptavidin-coated paramagnetic beads
(Promega) were added to the mixture and incubated at 37.degree. C.
for 20 min to allow the hybrids to bind to the bead surface. The
beads were then washed twice with 150 .mu.l of washing buffer [10
mM Tris-HCl (pH 7.5), 0.5% Nonidet P-40, and 1.5 mM MgCl.sub.2, and
50 mM KCl] to remove nonhybridized probes, as well as GnSCN,
proteins, nucleic acids, and any potential PCR inhibitors. During
each wash, the beads were drawn to the wall of the assay tube by
placing the tube on a Magnetic Separation Stand (Promega), enabling
the supernatant to be removed by aspiration. The hybrids were then
resuspended in 20 .mu.l ligase solution [66 mM Tris HCl (pH 7.5), 1
mM dithiothreitol, 1mM ATP, 1 mM MnCL.sub.2, 5 mM MgCl.sub.2, and 5
units of T4 DNA ligase (Boehringer Mannheim)] and incubated at
37.degree. C. for one hour to covalently link the probes that are
hybridized to adjacent positions on the RNA target, thus producing
the ligated amplification probe described in Example 5. Ten .mu.l
of the ligation reaction mixture (including beads) were then
transferred to 20 .mu.l of a PCR mixture containing 0.66 .mu.M of
PCR primer 3 and 0.66 .mu.M of PCR primer 4 as described in Example
5, 1.5 units of Taq DNA polymerase, 0.2 mM DATP, 0.2 mM dCTP, 0.2
mM dGTP, 0.2 mM dTTP, 1.5 mM MgCl.sub.2, 10 mM Tris-HCl (pH 8.3),
and 50 mM KCl. The first PCR reaction was incubated at 90.degree.
C. for 30 sec, 55.degree. C. for 30 sec and 72.degree. C. for 1 min
for 35 cycles in a GeneAmp PCR System 9600Thermocycler
(Perkin-Elmer, Norwalk, Conn.). After the first PCR, 5 .mu.l of
each reaction mixture were transferred into a 30-.mu.l second PCR
mixture containing the same components except that 0.66 .mu.M of
PCR primer 3 and 0.66 .mu.M of PCR primer 5 were used for
semi-nested PCR. The second PCR reaction was performed by the same
protocol as the first PCR reaction. Ten .mu.l of the second PCR
reaction were analyzed by electrophoresis through a 6%
polyacrylamide gel and visualized by ultraviolet fluorescence after
staining with ethidium bromide. The presence of a 102 basepair band
for the second PCR product was considered as a positive result. All
tests were duplicated and done blindly to the serological status
(anti-HCV positive or negative) of the sample.
RT-PCR was performed according to the method of Abe et al. (1994)
International Hepatology Communication 2: 352. Briefly, 15 .mu.l of
RNA suspension of each specimen was used as template to detect HCV
RNA and beta actin RNA. The beta actin RNA was used internal
positive control for cellular RNA. The sequence of outer primers
used for RT-PCR are, for HCV RNA, 5'-GCGACACTCCACCATAGAT-3' (sense)
(SEQ ID NO: 32) and 5'-GCTCATGGTGCACGGTCTA-3' (antisense) (SEQ ID
NO: 33) and for beta-actin RNA. 5'-CTTCTACAATGAGCTGCGTGTGGCT-3'
(sense) (SEQ ID NO : 34) and 5'-CGCTCATTGCCAATGGTGATGACCT-3'
(antisense) (SEQ ID NO : 35). The sequence of inner primers are,
for HCV RNA, 5'-CTGTGAGGAACTACTGTCT-3' (sense) (SEQ ID NO : 36) and
5'- ACTCGCAAGCACCCTATCA-3' (antisense) SEQ ID NO : 37), and for
beta-actin RNA. 5'- AAGGCCAACCGCGAGAAGAT-3' (sense) (SEQ ID NO: 38)
and 5'-TCACGCACGATTTCCCGC-3' (antisense) (SEQ ID NO : 39). The
first PCR reaction was combined with the reverse transcription step
in the same tube containing 50 .mu.l of reaction buffer prepared as
follows: 20 units of Rnase inhibitor (Promega). 100 units of
Moloney murine leukemia virus reverse transcriptase (Gibco BRL),
100 ng of each outer primer, 200 .mu.M of each of the four
deoxynucleotides, 1 unit of Taq DNA polymerase (Boehringer
Mannheim) and 1.times.Taq buffer containing 1.5 mM MgCl.sub.2. The
thermocycler was programmed to first incubate the samples of 50 min
at 37.degree. C. for the initial reverse transcription step and
then to carry out 35 cycles consisting of 94.degree. C. for 1 min,
55.degree. C. for 1 min, and 72.degree. C. for 2min. For the second
PCR, 5 .mu.l of the first PCR product was added to a tube
containing the second set of each inner primer, deoxynucleotides,
Taq DNA polymerase and Taq buffer as in the first PCR reaction, but
without reverse transcriptase and Rnase inhibitor. The second PCR
reaction was performed with the same protocol as the first PCR
reaction but without the initial 50 min incubation at 37.degree. C.
Twenty .mu.l of the PCR products were examined by electrophoresis
through a 2% agarose gel. Positive results of HCV RNA and
beta-actin RNA were indicated by the presence of second PCR
products as a 268-basepair and a 307-basepair band, respectively.
The results of LD-PCR and RT-PCR are set forth below in Table
2.
TABLE 2 Comparison of LD-PCR with RT-PCR FFPE.sup.a Unfixed.sup.b
LD-PCR.sup.c RT-PCR.sup.d RT-PCR.sup.e HCV Serology (No) + - + - +
- Anti-HCV + (13) 13 0 5 8 7.sup.f 0 Anti-HCV - (9) 5 4 0 9 6.sup.g
1 .sup.a FFPE formalin fixed paraffin embedded liver tissues.
.sup.b Unfixed snap frozen liver tissues of corresponding FFPE
specimens. .sup.c Number of FFPE specimens tested positive (+) or
negative (-) by ligation-dependent PCR. .sup.d Number of FFPE
specimens tested positive (+) or negative (-) by reverse
transcription PCR. .sup.e Number of specimens confirmed by RT-PCR
using unfixed frozen tissues. .sup.f Only 7 unfixed specimens were
available for confirmatory RT-PCR test. .sup.g Only 7 unfixed
specimens were available for confirmatory RT-PCR test.
Of the twenty-two FFPE specimens, thirteen were obtained from
patients who were HCV positive by EIA assay and nine were HCV
negative (Table 2). HCV RNA was detected in all thirteen
seropositive FFPE specimens by LD-PCR, whereas only five were
positive by RT-PCR. For confirmation, unfixed frozen liver
specimens available from seven cases were tested by RT-PCR. Of
these seven cases, HCV-RNA was detectable in all seven by LD-PCR
when FFPE tissue of the same specimens were utilized, but in only
one by RT-PCR. However, RT-PCR on the frozen tissue confirmed the
presence of HCV-RNA in all cases. Beta actin mRNA was detected in
all corresponding specimens, indicating minimal RNA degradation.
These results confirmed the preservation of the HCV RNA during
formalin-fixation, the heated paraffin embedding process, and up to
three years of storage. The overall sensitivity of RT-PCR on FFPE
specimens was 23.8% (5/21) in this study while it was determined
58.6% and 84% in prior studies by El-Batonony et al. (1994) J. Med.
Virol. 43: 380 and Abe et al. The gross difference in these values
was due to the difference in the selection of specimens in these
studies (eight RT-PCR negatives and five positives on FFPE tissues
were selected for this study). Among the eight HCV sero-negative
liver specimens, seven with HCC were removed from two patients with
primary biliary cirrhosis (PBS), two with alcoholic cirrhosis, two
with hepatitis B virus (HBV) liver cirrhosis, one with cryptogenic
liver cirrhosis and one without HCC from a child with biliary
atresia (Table 3). Among the seven HCC liver specimens, five tested
positive for HCV by LD-PCR, but none by RT-PCR. The specimen with
biliary atresia remained negative by both PCR tests. To resolve
this discrepancy, RT-PCR was performed on the seven unfixed frozen
tissue specimens. The results are set forth below in Table 3.
TABLE 3 HCV RNA detected in HCV-seronegative cases Clinical
FFPE.sup.b Unfixed.sup.c Total confirmed Diagnosis (No).sup.a
LD-PCR.sup.d RT-PCR.sup.d RT-PCR.sup.e Positive PBC (2) 1 0 2 2
Alcoholic (2) 2 0 2 2 Biliary 0 0 N/D 0 atresia (1) HBV (3) 2 0
2.sup.g 2 Crytogenic (1) 0 0 0 0 .sup.a Liver specimens from
patients with various clinical diagnosis: PBC primary biliary
cirrhosis, Alcoholic alcoholic liver cirrhosis, HBV positive for
HBsAg, cryptogenic cryptogenic liver cirrhosis. .sup.b FFPE
formalin fixed paraffin embedded liver tissues. .sup.c Unfixed snap
frozen, unfixed liver tissues of corresponding FFPE specimens.
.sup.d Number of FFPE specimens tested positive for HCV RNA by
LD-PCR or RT-PCR. .sup.e Number of specimens confirmed by RT-PCR
using unfixed frozen tissues. .sup.g Only 2 unfixed specimens were
available for confirmatory RT-PCR test. N/D not done no fresh
frozen specimen available.
The RT-PCR results on unfixed tissue confirmed the LD-PCR results,
indicating false negative results by serologic testing. In
addition, one of the PBC specimens that tested negative by both
LD-PCR and RT-PCR on FFPE specimens was positive by RT-PCR on an
unfixed frozen specimen, indicating false negative results by both
PCRs on the FFPE specimen. These results show that there is a high
detection rate of HCV RNA in HCV seronegative HCC (6/8, 75%) (Table
3) and that the overall positive rate in both HCV seropositive and
seronegative HCC specimens is 86% (18/21) (Table 2). Contamination
was unlikely since the cutting of FFPE and unfixed specimens, and
the PCR assays were performed in two separate laboratories. In
addition, great precaution was taken in the specimen preparation
and PCR testing with proper negative controls. The overall
agreement between LD-PCR of FFPE specimens and RT-PCR on fresh
frozen specimens is very high, and the sensitivity of LD-PCR is 95%
(18/19).
The foregoing results suggest that crosslinks caused by formalin
fixation disrupt chain elongation of the nascent DNA strand by
reverse transcriptase, resulting in lower sensitivity of RT-PCR in
FFPE tissue. In contrast, LD-PCR amplifies probe sequences,
bypassing the step of primer extension along the cross-linked
template. In addition, the amplification probes may only have a
30-nucleotide long complementary region, and therefore are more
accessible to the non-crosslinked regions. LD-PCR can thus achieve
a higher sensitivity in the detection of HCV RNA in FFPE specimens.
The value of this sensitive assay is confirmed by the foregoing
results, which evidence a high detection rate of HCV RNA even in
seronegative specimens.
EXAMPLE 10
PRIMER EXTENSION-DISPLACEMENT ON CIRCULAR AMPLIFICATION
SEQUENCE
This example demonstrates the ability of Klenow fragment of DNA
polymerase to displace downstream strands and produce a
polymer.
A synthetic DNA target was detected by mixing 10.sup.12 molecules
of phosphorylated circularizable probe having SEQ ID NO:31 with
10.sup.13 molecules of synthetic HCV DNA target in 10 .mu.l of
1.times.ligation buffer, heating at 65.degree. C. for two minutes,
and cooling to room temperature for ten minutes. One .mu.l of
ligase was added to the mix and incubated at 37.degree. C. for one
hour, followed by addition of 10.sup.13 molecules of .sup.32
P-labeled Ext-primer having SEQ ID NO:27. The mixture was heated to
100.degree. C. for five minutes and then cooled to room temperature
for twenty minutes. Forty .mu.l of Klenow mix and dNTPs were added
to the reaction and incubated at 37.degree. C. Ten .mu.l aliquots
were removed at 0, 1, 2 and 3 hours and examined on an 8%
polyacrylamide gel. The results are shown in FIG. 18. The left
lanes depict results in the absence of ligase. The right lanes
depict extension after ligation. Bands ranging from 105 to 600
bases can be visualized in the right lanes. The results demonstrate
that Klenow is able to extend from Ext-primer, displace the
downstream strand, and generate polymers.
EXAMPLE 11
DETECTION OF EBV EARLY RNA (EBER-1) IN PAROTID PLEOMORPHIC ADENOMAS
BY LIGATION DEPENDENT PCR
LD-CR utilizing a circularized probe was performed to detect
Epstein Barr virus early RNA (EBER-1) in salivary benign mixed
tumors (BMT). Six specimens of BMT and adjacent parotid tissue, and
three specimens of normal parotid tissue (two removed from cysts
and one from a hyperplastic lymph node) were snap frozen in
embedding medium for frozen tissue specimens (OCT, Miles, Inc.,
Elkhart, Ind.) and liquid nitrogen, and stored at -70.degree. C.
The corresponding formalin fixed paraffin embedded (FFPE) blocks of
tissue were obtained and studied in parallel to the fresh tissue.
All tissue was sectioned on a microtome, the blade of which was
cleaned with 10% Chlorox between cases to avoid cross
contamination. Two to three sections of each specimen were placed
in a 1.5 ml microcentrifuge tube. FFPE tissues were deparafinized
by incubating at 60.degree. C. for 10 minutes with 1 ml xylene
(Sigma), which was subsequently removed by two washes with absolute
ethanol. These specimens were dried by placing on a hot block at
65.degree. C. for 30 minutes. Deparaffinized tissue was lysed by
incubation at 100.degree. C. for 30 minutes, then 65.degree. C. for
30 minutes in 250 .mu.l of lysis buffer: 5M guanidium thiocyanate
(GTC)(Fluke), 0.5% bovine serum albumin (Sigma). 80 mM EDTA, 400 mM
Tris HCl (pH 7.5), and 0.5% sodium-N-lauroylsarcosine (Sigma).
Fresh frozen tissue was lysed by incubation at 37.degree. C. for 60
minutes in the same lysis buffer. The lysed specimens were stored a
-20.degree. C. until use.
Two capture/amplification probes designed to flank the region of
EBER-1 were used to capture target RNA. The sequences for capture
probe 1 (SEQ ID NO : 40) and capture/amplification probe 2 (SEQ ID
NO : 41) are shown in Table 4. The circular amplification probe
(SEQ ID NO : 42) was designed with 3' and 5' regions complementary
to the chosen target sequence (Table 4). Interposed between these
two regions is a noncomplementary linker sequence. This circular
amplification probe circularized upon target hybridization in such
a manner as to juxtapose the 5' and 3' ends. Seminested PCR was
performed using primer pairs directed as this linker sequence, also
shown in Table 4.
TABLE 4 Sequences of Capture Probes, Amplifiable Circular Target
Probe, and PCR Primers EBER-Cap Amp-1
5'-Biotin-AAGAgtctcctccctagcaaaacctctagggcagcgtaggtcctg-3' (SEQ ID
No. 40) EBER-Cap Amp-2
5'-Boitin-AAGAggatcaaaacatgcggaccaccagctggtacttgaccgaag-3' (SEQ ID
No. 41) Circular Amp PROBE 5'
tcaccacccgggacttgtacccgggacTGTCTGTGTATCTGCTAACCAAGAGCAA
CTACACGAATTCTCGATTAGGTTACTGCgggaagacaaccacagacaccgttcc-3' (SEQ ID
No. 42) 1st PCR primer pairs: GTTAGCAGATACACAGAC (sense SEQ ID NO.
27) CAAGAGCAACTACACGAA (antisense SEQ ID NO. 28) 2ND PCR primer
pairs: GTTAGCAGATACACAGAC (sense SEQ ID NO. 27) TTCTCGATTAGGTTACTG
(antisense SEQ ID NO. 29) (lower case -- complementary to EBER-1,
upper case - generically designed)
LD-PCR was performed as follows. Briefly, 80 .mu.l of lysis mixture
were added to 120 .mu.l of hybridization buffer (0.5% bovine serum
albumin, 80 mM EDTA, 400 MM Tris-HCl (pH 7.5), and 0.5%
sodium-N-lauroylsarcosine (Sigma) which contained 10.sup.10
molecules of phosphorylated target probe, and 10.sup.11 molecules
of capture probe 1 and capture probe 2. Addition of the
hybridization buffer reduced the GnSCN concentration from 5M to 2M
to allow hybridization to occur. This mixture was incubated for one
hour to allow the formation of hybrids, consisting of two DNA
capture/amplification probes and one DNA circular amplification
probe hybridized on the target RNA. Thirty .mu.l of
streptavidin-coated paramagnetic beads (Promega) were added to the
mixture and incubated at 37.degree. C. for 20 minutes to allow the
hybrids to bond to the bead surface. The beads were washed twice
with 150 .mu.l of washing buffer (10 mM Tris HCl (pH 7.5), 0.5%
Nonidet P-40, and 1.5 mM MgCl.sub.2 and 50 mM KCl) to remove
nonhybridized probes as well as potential inhibitors of PCR (GTC,
proteins) and potential sources of nonspecific PCR products
(cellular nucleic acids). During each wash, the beads were drawn to
the wall of the assay tube by placing the tube on a Magnetic
Separation Stand (Promega), enabling the supernatant to be removed
by aspiration. The 3' and 5' ends of the circular amplification
probes hybridized directly adjacent to each other on the target
RNA, were covalently linked, and hence circularized by incubation
at 37.degree. C. for 1 hour with 20 .mu.l ligase solution (66 mM
Tris HCl (pH 7.5), 1 mM dithiothreitol, 1 mM ATP. 1mM MnCl.sub.2
and 5 units of T4DNA ligase (Boerhinger)). Ten .mu.l of the
ligation mixture, including paramagnetic beads, were transferred to
20 .mu.l of a PCR mixture containing 0.66 .mu.M of PCR primer, 0.5
units Taq DNA polymerase, 0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dGTP,
0.2 mM dTTP, 1.5 mM Mg.sub.2, and 10 mM Tris-HCl (pH 8.3) and 50 mM
KCl. The first PCR reaction was incubated at 94.degree. C. for 30
seconds, 55.degree. C. for 30 seconds, and 72.degree. C. for 1
minute for 35 cycles in a GeneAmp PCR system 9600 thermocycler
(Perkin Elmer, Conn.). After the first PCR, 5 ul of each reaction
mixture were transferred into a 25 ul second PCR mixture containing
the same components except that 0.66 .mu.M of PCR primer 1 and 0.66
.mu.M of PCR primer 3 were used for seminested PCR, which increases
signal detection sensitivity without comprising amplification
specificity. Extension of PCR primer along the covalently
circularized probe results in the generation of a large multi-unit
polymer (rolling circle polymerization). In fact, without digestion
into monomeric units, the PCR polymer product cannot migrate into
the polyacrylamide gel. Ten .mu.l of the second PCR reaction were
digested with restriction endonuclease EcoRI in the present of 50
mM NaCl, 100 mM Tris-HCl (pH 7.5). 10 mM MgCl.sub.2, 0.025% Triton
X-100, and analyzed by gel electrophoresis through a 6%
polyacrylamide gel and visualized by ultraviolet fluorescence after
staining with ethidium bromide. The presence of a 90 base-pair
(second PCR product) and a 108 base-pair product (1st PCR) are
considered as a positive result. The results are summarized in
Table 5.
TABLE 5 EBV early RNA (EBER-1) detected by LD-PCR Parotid tissue
Pleomorphic Adenoma Case (frozen) (frozen) FFPE 1 positive none
positive 2 negative none negative 3 negative none ND 4 ND positive
negative 5 positive positive negative 6 positive positive positive
7 positive positive negative 8 positive positive negative 9
positive negative negative Note Case 1 and 2 were from parotid
tissues removed for reasons other than pleomorphic adenoma. Cases
3-8 contained pleomorphic adenoma. FFPE formalin fixed paraffin
embedded tissue. Frozen-tissue snap frozen in liquid nitrogen. ND
not done as tissue not available.
In sum, EBER-1 sequences were detected in six of eight parotid
samples. Of the six pleomorphic adenomas studied, four were
positive for EBER-1. Of the two cases in which EBER was not
detected in the tumor, sequences were present within surrounding
parotid tissue. The detection of EBER-1 sequences within
corresponding formalin-fixed paraffin embedded tissue was
considerably less sensitive-only two of eight specimens were
positive.
In summary, the present results with ligation dependent PCR
utilizing a circular probe demonstrate the presence of EBV-related
sequences within the majority of pleomorphic adenomas studied.The
present method exhibits a markedly increased detection rate
relative to standard PCR for the detection of EBV DNA as performed
by Taira et al. (1992) J. of Otorhinolarynqol Soc. Jap. 95: 860. In
the present method, the 3' and 5' ends of a circularizable probe
hybridized to the target sequence, resulting in juxtaposition. The
justaposed sequences were then ligated, resulting in a circularized
covalently linked probe that was locked onto the target sequence
and thus resistant to stringent washes,. PCR on the circular probe
produced a rolling circle polymer, which was digested into
monomeric units and visualized on a gel. The use of ligation
dependent PCR with a circular probe, followed by detection by
amplification of the probe by the rolling circle model, resulted in
tremendous sensitivity of target detection in fresh frozen
tissue.
Various publications are cited therein, the contents of which are
hereby incorporated by reference in their entireties.
SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF
SEQUENCES: 42 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE
CHARACTERISTICS: (A) LENGTH: 59 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:
DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_feature (B)
LOCATION: 1..59 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: CCATCTTCCT
GCTAATTTTA AGACCTGGTA ACAGGATTTC CCCGGGAATT CAAGCTTGG 59 (2)
INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 92 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix)
FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..92 (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 2: GGGTTGACCC GGCTAGATCC
GGGTGTGTCC TCTCTAACTT TCGAGTAGAG AGGTGAGAAA 60 ACCCCGTTAT
CTGTATGTAC TGTTTTTACT GG 92 (2) INFORMATION FOR SEQ ID NO: 3: (i)
SEQUENCE CHARACTERISTICS: (A) LENGTH: 151 base pairs (B) TYPE:
nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)
MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY:
misc_feature (B) LOCATION: 1..151 (xi) SEQUENCE DESCRIPTION: SEQ ID
NO: 3: GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT TCGAGTAGAG
AGGTGAGAAA 60 ACCCCGTTAT CTGTATGTAC TGTTTTTACT GGCCATCTTC
CTGCTAATTT TAAGACCTGG 120 TAACAGGATT TCCCCGGGAA TTCAAGCTTG G 151
(2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 90 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix)
FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..90 (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 4: GGGTTGACCC GGCTAGATCC
GGGTGTGTCC TCTCTAACTT TCGAGTAGAG AGGTGAGAAA 60 ACCCCGTTAT
CCTGGTAACA GGATTTCCCC 90 (2) INFORMATION FOR SEQ ID NO: 5: (i)
SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE:
nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)
MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY:
misc_feature (B) LOCATION: 1..21 (xi) SEQUENCE DESCRIPTION: SEQ ID
NO: 5: CAAGCTTGAA TTCCCGGGGA A 21 (2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE:
nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)
MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY:
misc_feature (B) LOCATION: 1..20 (xi) SEQUENCE DESCRIPTION: SEQ ID
NO: 6: GGGTTGACCC GGCTAGATCC 20 (2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 base pairs (B) TYPE:
nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)
MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY:
misc_feature (B) LOCATION: 1..54 (xi) SEQUENCE DESCRIPTION: SEQ ID
NO: 7: CAGGCTTATC CCGAAGTGCC TGGTAACAGG ATTTCCCCGG GAATTCAAGC TTGG
54 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 91 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix)
FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..91 (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 8: GGGTTGACCC GGCTAGATCC
GGGTGTGTCC TCTCTAACTT TCGAGTAGAG AGGTGAGAAA 60 ACCCCGTTAT
CCGGTATTAG ACCCAGTTTC C 91 (2) INFORMATION FOR SEQ ID NO: 9: (i)
SEQUENCE CHARACTERISTICS: (A) LENGTH: 145 base pairs (B) TYPE:
nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)
MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY:
misc_feature (B) LOCATION: 1..145 (xi) SEQUENCE DESCRIPTION: SEQ ID
NO: 9: GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT TCGAGTAGAG
AGGTGAGAAA 60 ACCCCGTTAT CCGGTATTAG ACCCAGTTTC CCAGGCTTAT
CCCGAAGTGC CTGGTAACAG 120 GATTTCCCCG GGAATTCAAG CTTGG 145 (2)
INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 56 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix)
FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..56 (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 10: GAAGACATGC ATCCCGTGGT
CCTGGTAACA GGATTTCCCC GGGAATTCAA GCTTGG 56 (2) INFORMATION FOR SEQ
ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 90 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:
linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A)
NAME/KEY: misc_feature (B) LOCATION: 1..90 (xi) SEQUENCE
DESCRIPTION: SEQ ID NO: 11: GGGTTGACCC GGCTAGATCC GGGTGTGTCC
TCTCTAACTT TCGAGTAGAG AGGTGAGAAA 60 ACCCCGTTAT CGCTAAAGCG
CTTTCCACCA 90 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE
CHARACTERISTICS: (A) LENGTH: 146 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:
DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_feature (B)
LOCATION: 1..146 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT TCGAGTAGAG AGGTGAGAAA
60 ACCCCGTTAT CGCTAAAGCG CTTTCCACCA GAAGACATGC ATCCCGTGGT
CCTGGTAACA 120 GGATTTCCCC GGGAATTCAA GCTTGG 146 (2) INFORMATION FOR
SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 56 base
pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:
linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A)
NAME/KEY: misc_feature (B) LOCATION: 1..56 (xi) SEQUENCE
DESCRIPTION: SEQ ID NO: 13: AAAGACATGC ATCCCGTGGT CCTGGTAACA
GGATTTCCCC GGGAATTCAA GCTTGG 56 (2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 90 base pairs (B) TYPE:
nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)
MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY:
misc_feature (B) LOCATION: 1..90 (xi) SEQUENCE DESCRIPTION: SEQ ID
NO: 14: GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT TCGAGTAGAG
AGGTGAGAAA 60 ACCCCGTTAT CGCTAAAGCG CTTTCCACCT 90 (2) INFORMATION
FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 146
base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)
TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION: 1..146 (xi) SEQUENCE
DESCRIPTION: SEQ ID NO: 15: GGGTTGACCC GGCTAGATCC GGGTGTGTCC
TCTCTAACTT TCGAGTAGAG AGGTGAGAAA 60 ACCCCGTTAT CGCTAAAGCG
CTTTCCACCT AAAGACATGC ATCCCGTGGT CCTGGTAACA 120 GGATTTCCCC
GGGAATTCAA GCTTGG 146 (2) INFORMATION FOR SEQ ID NO: 16: (i)
SEQUENCE CHARACTERISTICS: (A) LENGTH: 55 base pairs (B) TYPE:
nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)
MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY:
misc_feature (B) LOCATION: 1..55 (xi) SEQUENCE DESCRIPTION: SEQ ID
NO: 16: GCAGACCACT ATGGCTCTCC CTGGTAACAG GATTTCCCCG GGAATTCAAG
CTTGG 55 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE
CHARACTERISTICS: (A) LENGTH: 90 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:
DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_feature (B)
LOCATION: 1..90 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
GGGTTGACCC GGCTAGATCC GGGTGTGTCC TCTCTAACTT TCGAGTAGAG AGGTGAGAAA
60 ACCCCGTTAT CCGGTGTACT CACCGGTTCC 90 (2) INFORMATION FOR SEQ ID
NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 145 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:
linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A)
NAME/KEY: misc_feature (B) LOCATION: 1..145 (xi) SEQUENCE
DESCRIPTION: SEQ ID NO: 18: GGGTTGACCC GGCTAGATCC GGGTGTGTCC
TCTCTAACTT TCGAGTAGAG AGGTGAGAAA 60 ACCCCGTTAT CCGGTGTACT
CACCGGTTCC GCAGACCACT ATGGCTCTCC CTGGTAACAG 120 GATTTCCCCG
GGAATTCAAG CTTGG 145 (2) INFORMATION FOR SEQ ID NO: 19: (i)
SEQUENCE CHARACTERISTICS: (A) LENGTH: 47 base pairs (B) TYPE:
nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)
MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY:
misc_feature (B) LOCATION: 1..47 (xi) SEQUENCE DESCRIPTION: SEQ ID
NO: 19: GGTGAAATTG CTGCCATTGT CTGTATGTTG TCTGTGTATC TGCTAAC 47 (2)
INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 65 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:
linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A)
NAME/KEY: misc_feature (B) LOCATION: 1..65 (xi) SEQUENCE
DESCRIPTION: SEQ ID NO: 20: CAAGAGCAAC TACACGAATT CTCGATTAGG
TTACTGCAGC AACAGGCGGC CTTAACTGTA 60 GTACT 65 (2) INFORMATION FOR
SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 112 base
pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:
linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A)
NAME/KEY: misc_feature (B) LOCATION: 1..112 (xi) SEQUENCE
DESCRIPTION: SEQ ID NO: 21: GGTGAAATTG CTGCCATTGT CTGTATGTTG
TCTGTGTATC TGCTAACCAA GAGCAACTAC 60 ACGAATTCTC GATTAGGTTA
CTGCAGCAAC AGGCGGCCTT AACTGTAGTA CT 112 (2) INFORMATION FOR SEQ ID
NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 base pairs (B)
TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY:
misc_feature (B) LOCATION: 1..45 (xi) SEQUENCE DESCRIPTION: SEQ ID
NO: 22: AAGAGCGTGA AGACAGTAGT TCCTCACAGG GGAGTGATTC ATGGT 45 (2)
INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix)
FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..45 (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 23: AAGACCCAAC ACTACTCGGC
TAGCAGTCTT GCGGGGGCAC GCCCA 45 (2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE:
nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)
MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY:
misc_feature (B) LOCATION: 1..51 (xi) SEQUENCE DESCRIPTION: SEQ ID
NO: 24: ACTCACCGGT TCCGCAGACC ACTATGGCTC GTTGTCTGTG TATCTGCTAA C 51
(2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 69 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix)
FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..69 (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 25: CAAGAGCAAC TACACGAATT
CTCGATTAGG TTACTGCAGA GGACCCGGTC GTCCTGGCAA 60 TTCCGGTGT 69 (2)
INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 120 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix)
FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..120 (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 26: CAAGAGCAAC TACACGAATT
CTCGATTAGG TTACTGCAGA GGACCCGGTC GTCCTGGCAA 60 TTCCGGTGTA
CTCACCGGTT CCGCAGACCA CTATGGCTCG TTGTCTGTGT ATCTGCTAAC 120 (2)
INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix)
FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..18 (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 27: GTTAGCAGAT ACACAGAC 18 (2)
INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix)
FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..18 (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 28: CAAGAGCAAC TACACGAA 18 (2)
INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix)
FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..18 (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 29: TTCTCGATTA GGTTACTG 18 (2)
INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 100 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix)
FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..100 (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 30: CAAGAGCAAC TACACGAATT
CTCGATTAGG TTACTGCAGC GTCCTGGCAA TTCCGGTGTA 60 CTCACCGGTT
CCGCAGACCG TTGTCTGTGT ATCTGCTAAC 100 (2) INFORMATION FOR SEQ ID NO:
31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 108 base pairs (B)
TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY:
misc_feature (B) LOCATION: 1..108 (xi) SEQUENCE DESCRIPTION: SEQ ID
NO: 31: CCTTTCGCGA CCCAACACTA CTCGGCTGTC TGTGTATCTG CTAACCAAGA
GCAACTACAC 60 GAATTCTCGA TTAGGTTACT GCGCACCCTA TCAGGCAGTA CCACAAGG
108 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE
CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:
cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:
<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:
SEQ ID NO: 32: GCGACACTCC ACCATAGAT 19 (2) INFORMATION FOR SEQ ID
NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B)
TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO
(v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 33: GCTCATGGTG CACGGTCTA 19 (2)
INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)
HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:
<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:
SEQ ID NO: 34: CTTCTACAAT GAGCTGCGTG TGGCT 25 (2) INFORMATION FOR
SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base
pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:
linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)
ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL
SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: CGCTCATTGC
CAATGGTGAT GACCT 25 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE
CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:
cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:
<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:
SEQ ID NO: 36: CTGTGAGGAA CTACTGTCT 19 (2) INFORMATION FOR SEQ ID
NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B)
TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO
(v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 37: ACTCGCAAGC ACCCTATCA 19 (2)
INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A)
LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)
HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:
<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:
SEQ ID NO: 38: AAGGCCAACC GCGAGAAGAT 20 (2) INFORMATION FOR SEQ ID
NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B)
TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO
(v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)
SEQUENCE DESCRIPTION: SEQ ID NO: 39: TCACGCACGA TTTCCCGC 18
(2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)
HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:
<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:
SEQ ID NO: 40: AAGAGTCTCC TCCCTAGCAA AACCTCTAGG GCAGCGTAGG TCCTG 45
(2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)
HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:
<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:
SEQ ID NO: 41: AAGAGGATCA AAACATGCGG ACCACCAGCT GGTACTTGAC CGAAG 45
(2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 109 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)
HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:
<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:
SEQ ID NO: 42: TCACCACCCG GGACTTGTAC CCGGGACTGT CTGTGTATCT
GCTAACCAAG AGCAACTACA 60 CGAATTCTCG ATTAGGTTAC TGCGGGAAGA
CAACCACAGA CACCGTTCC 109
* * * * *